Document:

exv4w1

Exhibit 4.1

ALEXZA PHARMACEUTICALS, INC.

WARRANT

dated as of May ___, 2011

     This Certifies That, for value received, [____________] or its successors or
permitted assigns (such Person and such successors and assigns each being the “Warrant Holder” with
respect to the Warrant (as herein defined) held by it), at any time and from time to time on or
after the six-month anniversary of the date of this Warrant and on or prior to the Expiration Date
(as herein defined), is entitled (a) to subscribe for the purchase from Alexza Pharmaceuticals,
Inc., a Delaware corporation (the “Company”), [__________] Shares (as herein defined) at a price
per Share equal to the Exercise Price (as herein defined), and (b) to the other rights set forth
herein; provided that the number of Shares issuable upon any exercise of this Warrant and the
Exercise Price shall be adjusted and readjusted from time to time in accordance with Section
4. By accepting delivery hereof, the Warrant Holder agrees to be bound by the provisions
hereof.

     This Warrant (the “Warrant”) is issued as part of a series of similar Warrants (collectively,
the “Warrants”) issued pursuant to that certain Securities Purchase Agreement, dated as of May 3,
2011, by and among the Company and the other parties identified therein (the “SPA”).

     In Furtherance Thereof, the Company irrevocably undertakes and agrees for the benefit
of Warrant Holder as follows:

     Section 1. Definitions and Construction.

     (a) Certain Definitions. As used herein (the following definitions being applicable in
both singular and plural forms):

     “Affiliate” means, with respect to any Person, any other Person that directly or indirectly
controls, is controlled by, or is under common control with such Person.

     “Appraised Value” means at any time the fair market value of a Share determined in good faith
by the Board of Directors of the Company as of a date which is within ten (10) days of the date as
of which the determination is to be made, subject to the rights of the Requisite Holders pursuant
to Section 4(j).

     “Business Day” means any day except a Saturday, Sunday or other day on which commercial banks
in New York City are authorized by law to close.

     “Closing Price” means, for any trading day with respect to a Share, (a) the last reported sale
price on such day on the principal national securities exchange on which the Shares are listed or
admitted to trading or, if no such reported sale takes place on any such day, the average of the
closing bid and asked prices thereon, as reported in The Wall Street Journal, or (b) if such Shares
shall not be listed or admitted to trading on a national securities exchange, the last reported
sales price on the NASDAQ National Market System or, if no such reported sale takes place on any
such day, the average of the closing bid and asked prices thereon, as reported in The Wall Street
Journal, or (c) if such Shares shall not be quoted on such National Market System nor listed or
admitted to trading on a national securities exchange, then the average of the closing bid and
asked prices, as reported by The Wall Street Journal for the over-the-counter market; provided that
if clause (a), (b), or (c) applies and no price is reported in The Wall
Street Journal for any trading day, then the price reported in The Wall Street Journal for the most
recent prior trading day shall be deemed to be the price reported for such trading day.

 

 

     “Commission” means the Securities and Exchange Commission or any other Federal agency
administering the Securities Act at the time.

     “Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor Federal
statute, and the rules and regulations of the Commission thereunder, all as the same shall be in
effect at the time.

     “Exercise Amount” means for any number of Warrant Shares as to which this Warrant is being
exercised the product of (i) such number of Warrant Shares times (ii) the Exercise Price.

     “Exercise
Price” means $1.755 per Warrant Share, as adjusted from time to time pursuant to
Section 4.

     “Expiration Date” means May [___], 2016.

     “Initial Holder” means [________________].

     “Person” means an individual, a corporation, a partnership, an association, a trust or any
other entity or organization, including a government or political subdivision or an agency or
instrumentality thereof.

     “Requisite Holders” means at any time holders of Warrants representing at least 75% of the
Warrant Shares issuable upon the exercise of all the outstanding Warrants.

     “Securities Act” means the Securities Act of 1933, as amended, or any successor Federal
statute, and the rules and regulations of the Commission thereunder, all as the same shall be in
effect at the time.

     “Shares” means shares of the Company’s currently authorized common stock, $0.0001 par value,
and stock of any other class or other consideration into which such currently authorized common
stock may hereafter have been changed into.

     “Warrant” means, as the context requires, this warrant and any successor warrant or warrants
issued upon a whole or partial transfer or assignment of any such Share purchase warrant or of any
such successor warrant.

     “Warrant Shares” means the number of Shares issued or issuable upon exercise of this Warrant
as set forth in the introduction hereto, as adjusted from time to time pursuant to Section
4, or in the case of other Warrants, issuable upon exercise of those Warrants.

     (b) Accounting Terms and Determinations. Unless otherwise specified herein, all
accounting terms used herein shall be interpreted, all accounting determinations hereunder shall be
made, and all financial statements required to be delivered hereunder shall be prepared, in
accordance with generally accepted accounting principles. When used herein, the term “financial
statements” shall include the notes and schedules thereto. References to fiscal periods are to
fiscal periods of the Company.

     (c) Computation of Time Periods. With respect to the computation of periods of time
from a specified date to a later specified date, the word “from” means “from and including” and the
words “to” and “until” each mean “to but excluding.” Periods of days shall be counted in calendar
days unless otherwise stated.

     (d) Construction. Unless the context requires otherwise, references to the plural
include the singular and to the singular include the plural, references to any gender include any
other gender, the part includes the whole, the term “including” is not limiting, and the term “or”
has, except where otherwise indicated, the inclusive meaning represented by the phrase “and/or.”
The words “hereof,” “herein,” “hereby,” “hereunder,” and similar terms in this Warrant refer to
this Warrant as a whole and not to any particular provision of this Warrant. Section, subsection,
clause, exhibit, appendix and schedule references are to this Warrant, unless otherwise specified.
Any reference to this Warrant includes any and all permitted alterations, amendments, changes,
extensions, modifications, renewals, or supplements thereto or thereof, as applicable.

2

 

     (e) Exhibits and Schedules. All of the exhibits, appendices and schedules attached
hereto shall be deemed incorporated herein by reference.

     (f) No Presumption Against Any Party. Neither this Warrant nor any uncertainty or
ambiguity herein or therein shall be construed or resolved using any presumption against any party
hereto or thereto, whether under any rule of construction or otherwise. On the contrary, this
Warrant has been reviewed by each of the parties and their counsel and, in the case of any
ambiguity or uncertainty, shall be construed and interpreted according to the ordinary meaning of
the words used so as to fairly accomplish the purposes and intentions of all parties hereto.

     Section 2. Exercise of Warrant.

     (a) Exercise and Payment. The Warrant Holder may exercise this Warrant in whole or in
part, at any time or from time to time on any Business Day on or prior to the Expiration Date, by
delivering to the Company a duly executed notice (a “Notice of Exercise”) in the form of
Exhibit A and by payment to the Company of the Exercise Amount, at the election of the
Warrant Holder, either (a) by wire transfer of immediately available funds to the account of the
Company in an amount equal to the Exercise Amount not later than three Business Days after the
Company receives the Notice of Exercise (a “Cash Exercise”), (b) by receiving from the Company the
number of Warrant Shares equal to (i) the number of Warrant Shares as to which this Warrant is
being exercised minus (ii) the number of Warrant Shares having a value, based on the Closing Price
on the trading day immediately prior to the date of such exercise (or if there is no such Closing
Price, then based on the Appraised Value as of such day), equal to the Exercise Amount (a “Cashless
Exercise”), or (c) by any combination of the foregoing. The Company acknowledges that the
provisions of clause (b) are intended, in part, to ensure that a full or partial exchange of this
Warrant pursuant to such clause (b) will qualify as a conversion, within the meaning of paragraph
(d)(3)(ii) of Rule 144 under the Securities Act. At the request of any Holder, the Company will
accept reasonable modifications to the exchange procedures provided for in this Section 2
in order to accomplish such intent. For all purposes of this Warrant (other than this Section
2(a)), any reference herein to the exercise of this Warrant shall be deemed to include a
reference to the exchange of this Warrant into Shares in accordance with the terms of clause (b).

     (b) Effectiveness and Delivery. The Company shall confirm receipt of any Notice of
Exercise delivered pursuant to Section 2(a) within one Business Day of the receipt thereof.
As soon as practicable but not later than three Business Days after the Company shall have received
such Notice of Exercise, and provided that payment of the Exercise Amount for a Cash Exercise has
been received by the Company, the Company shall execute and deliver or cause to be executed and
delivered, in accordance with such Notice of Exercise, a certificate or certificates representing
the number of Shares specified in such Notice of Exercise, which shall take into account the
Exercise Price for a Cashless Exercise, issued in the name of the Warrant Holder or in such other
name or names of any Person or Persons designated in such Notice of Exercise. Without prejudice to
the holding periods determined under Rule 144 under the Securities Act, this Warrant shall be
deemed to have been exercised and such Share certificate or certificates shall be deemed to have
been issued, and the Warrant Holder or other Person or Persons designated in such Notice of
Exercise shall be deemed for all purposes to have become a holder of record of Shares, all as of
the date that such Notice of Exercise shall have been received by the Company.

     (c) Surrender of Warrant. The Warrant Holder shall surrender this Warrant to the
Company within five Business Days after it delivers the Notice of Exercise, and in the event of a
partial exercise of the Warrant, the Company shall execute and deliver to the Warrant Holder, at
the time the Company delivers the Share certificate or certificates issued pursuant to such Notice
of Exercise, a new Warrant for the unexercised portion of the Warrant, but in all other respects
identical to this Warrant.

     (d) Fractional Shares. The Company shall not be required to issue fractions of Shares
upon an exercise of the Warrant. If any fraction of a Share would, but for this restriction, be
issuable upon an exercise of the Warrant, in lieu of delivering such fractional Share, the Company
shall pay to the Warrant Holder, in

3

 

cash, an amount equal to the same fraction times the Closing Price on the trading day immediately
prior to the date of such exercise (or if there is no such Closing Price, then based on the
Appraised Value as of such day).

     (e) Expenses and Taxes. The Company shall pay all expenses, taxes and owner charges
payable in connection with the preparation, issuance and delivery of certificates for the Warrant
Shares and any new Warrants, except that if the certificates for the Warrant Shares or the new
Warrants are to be registered in a name or names other than the name of the Warrant Holder, funds
sufficient to pay all transfer taxes payable as a result of such transfer shall be paid by the
Warrant Holder at the time of its delivery of the Notice of Exercise or promptly upon receipt of a
written request by the Company for payment.

     (f) Automatic Cashless Exercise. To the extent that the Closing Price on the trading
day immediately prior to the Expiration Date (or if there is no such Closing Price, then based on
the Appraised Value as of such day) is greater than the Exercise Price and there has not been an
exercise by the Warrant Holder pursuant to Section 2(a) hereof, any portion of the Warrant
that remains unexercised shall be exercised automatically in whole (not in part), upon the
Expiration Date. Payment by the Warrant Holder upon such automatic exercise shall be in the form of
the Warrant Holder receiving from the Company the number of Warrant Shares equal to (i) the number
of Warrant Shares as to which this Warrant is being automatically exercised minus (ii) the number
of Warrant Shares having a value, based on the Closing Price on the trading day immediately prior
to the date of such automatic exercise (or if there is no such Closing Price, then based on the
Appraised Value as of such day), equal to the Exercise Amount.

     Section 3. Validity of Warrant and Issuance of Shares.

     (a) The Company represents and warrants that this Warrant has been duly authorized, is validly
issued, and constitutes the valid and binding obligation of the Company and is enforceable against
the Company in accordance with its terms.

     (b) The Company further represents and warrants that on the date hereof it has duly authorized
and reserved, and the Company hereby agrees that it will at all times until the Expiration Date
have duly authorized and reserved, such number of Shares as will be sufficient to permit the
exercise in full of the Warrant, and that all such Shares are and will be duly authorized and, when
issued upon exercise of the Warrant, will be validly issued, fully paid and non-assessable, and
free and clear of all security interests, claims, liens, equities and other encumbrances.

     Section 4. Adjustment Provisions. The Exercise Price in effect at any time, and the
number of Warrant Shares that may be purchased upon any exercise of the Warrant, shall be subject
to change or adjustment as follows:

     (a) Share Reorganization. If the Company shall subdivide its outstanding Shares into a
greater number of Shares, by way of a stock split, stock dividend or otherwise, or consolidate its
outstanding Shares into a smaller number of Shares (any such event being herein called a “Share
Reorganization”), then (i) the Exercise Price shall be adjusted, effective immediately after the
effective date of such Share Reorganization, to a price determined by multiplying the Exercise
Price in effect immediately prior to such effective date by a fraction, the numerator of which
shall be the number of Shares outstanding on such effective date before giving effect to such Share
Reorganization and the denominator of which shall be the number of Shares outstanding after giving
effect to such Share Reorganization, and (ii) the number of Shares subject to purchase upon
exercise of this Warrant shall be adjusted, effective at such time, to a number determined by
multiplying the number of Shares subject to purchase immediately before such Share Reorganization
by a fraction, the numerator of which shall be the number of Shares outstanding after giving effect
to such Share Reorganization and the denominator of which shall be the number of Shares outstanding
immediately before giving effect to such Share Reorganization.

     (b) Special Distributions. If the Company shall issue or distribute to any holder or
holders of Shares evidences of indebtedness, any other securities of the Company or rights or
warrants to subscribe for or

4

 

purchase any security of the Company or any cash, property or other assets (excluding a Share
Reorganization), whether or not accompanied by a purchase, redemption or other acquisition of
Shares (any such nonexcluded event being herein called a “Special Distribution”), then the Warrant
Holder shall be entitled to a pro-rata share of such Special Distribution as though the Warrant
Holder had fully exercised this Warrant immediately prior to the record date for such Special
Distribution, and the Company shall pay or distribute such pro-rata share to Warrant Holder when
paid or distributed to the holders of the Shares. A reclassification of the Shares (other than a
change in par value, or from par value to no par value or from no par value to par value) into
shares of any other class of stock shall be deemed to be a distribution by the Company to the
holders of its Shares of such class of stock and, if the outstanding Shares shall be changed into a
larger or smaller number of Shares as part of such reclassification, a Share Reorganization.

     (c) Capital Reorganization. Without limiting any of the other provisions hereof, if
any (i) capital reorganization; (ii) reclassification of the capital stock of the Company; (iii)
merger, consolidation or reorganization or other similar transaction or series of related
transactions which results in the voting securities of the Company outstanding immediately prior
thereto representing immediately thereafter (either by remaining outstanding or by being converted
into voting securities of the surviving or acquiring entity) less than 50% of the combined voting
power of the voting securities of or economic interests in the Company or such surviving or
acquiring entity outstanding immediately after such merger, consolidation or reorganization; (iv)
sale, lease, license, transfer, conveyance or other disposition of all or substantially all of the
assets of the Company; (v) sale of shares of capital stock of the Company, in a single transaction
or series of related transactions, representing at least 50% of the voting power of the voting
securities of or economic interests in the Company; or (vi) the acquisition by any “person”
(together with his, her or its Affiliates) or “group” (within the meaning of Section 13(d) or 14(d)
of the Exchange Act) acquires, directly or indirectly, the beneficial ownership (as such term is
defined in Rule 13d-3 promulgated under the Exchange Act) of outstanding shares of capital stock
and/or other equity securities of the Company, in a single transaction or series of related
transactions (including, without limitation, one or more tender offers or exchange offers),
representing at least 50% of the voting power of or economic interests in the then outstanding
shares of capital stock of the corporation (each of (i)-(vi) above a “Corporate Reorganization”)
shall be effected, then the Company shall use its commercially reasonable efforts to ensure that
lawful and adequate provision shall be made whereby each Warrant Holder shall thereafter continue
to have the right to purchase and receive upon the basis and upon the terms and conditions herein
specified and in lieu of the Warrant Shares issuable upon exercise of the Warrants held by such
Warrant Holder, shares of stock in the surviving or acquiring entity (“Acquirer”), as the case may
be, such that the aggregate value of the Warrant Holder’s warrants to purchase such number of
shares, where the value of each new warrant to purchase one share in the Acquirer is determined in
accordance with the Black-Scholes Option Pricing formula set forth in Appendix A hereto, is
equivalent to the aggregate value of the Warrants held by such Warrant Holder, where the value of
each Warrant to purchase one share in the Company is determined in accordance with the
Black-Scholes Option Pricing formula set forth Appendix B hereto. Furthermore, the new
warrants to purchase shares in the Acquirer referred to herein shall have the same expiration date
as the Warrants, and shall have a strike price, KAcq, that is calculated in accordance
with Appendix A hereto. For the avoidance of doubt, if the surviving or acquiring entity,
as the case may be, is a member of a consolidated group for financial reporting purposes, the
parent of such consolidated group shall be deemed to be the Acquirer for purposes of this
Section 4(c) and Appendix A hereto.

Moreover, appropriate provision shall be made with respect to the rights and interests of each
Warrant Holder to the end that the provisions hereof (including, without limitation, provision for
adjustment of the Warrant Price) shall thereafter be applicable, as nearly equivalent as may be
practicable in relation to any shares of stock thereafter deliverable upon the exercise thereof.
The Company shall not effect any such Corporate Reorganization unless prior to or simultaneously
with the consummation thereof the successor corporation resulting from such consolidation or
merger, or the corporation purchasing or otherwise

5

 

acquiring such assets or other appropriate corporation or entity shall assume by written
instrument, reasonably deemed by the Board of Directors of the Company and the Requisite Holders to
be satisfactory in form and substance, the obligation to deliver to the holder of the Warrants, at
the last address of such holder appearing on the books of the Company, such shares of stock, as, in
accordance with the foregoing provisions, such holder may be entitled to purchase, and the other
obligations under these Warrants. The provisions of this Section 4(c) shall similarly apply
to successive Corporate Reorganizations. If the Company, in spite of using its commercially
reasonable efforts, is unable to cause these Warrants to continue in full force and effect until
the Expiration Date in connection with any Corporate Reorganization, then the Company shall pay the
Warrant Holders an amount per Warrant to purchase one share in the Company that is calculated in
accordance with the Black-Scholes Option Pricing formula set forth in Appendix B hereto.
Such payment shall be made, promptly following the closing of the Corporate Reorganization, in cash
in the event that the Corporate Reorganization results in the stockholders of the Company receiving
cash from the Acquirer at the closing of the transaction, and shall be made in shares of the
Company (with the value of each share in the Company is determined according to SCorp in
Appendix B hereto) in the event that the Corporate Reorganization results in the
stockholders of the Company receiving shares in the Acquirer or other entity at the closing of the
transaction. In the event that the stockholders of the Company receive both cash and shares at the
closing of the transaction, such payment to the Warrant Holders shall be also be made in both cash
and shares in the same proportion as the consideration received by the stockholders.

     (d) Adjustment Rules.

          (i) Any adjustments pursuant to this Section 4 shall be made successively whenever any
event referred to herein shall occur, except that, notwithstanding any other provision of this
Section 4, no adjustment shall be made to the number of Warrant Shares to be delivered to
the Warrant Holder (or to the Exercise Price) if such adjustment represents less than 1% of the
number of Warrant Shares previously required to be so delivered, but any lesser adjustment shall be
carried forward and shall be made at the time and together with the next subsequent adjustment
which together with any adjustments so carried forward shall amount to 1% or more of the number of
Warrant Shares to be so delivered.

          (ii) No adjustments shall be made pursuant to this Section 4 in respect of the
issuance of Warrant Shares upon exercise of the Warrant;

          (iii) If the Company shall take a record of the holders of its Shares for any purpose referred
to in this Section 4, then (x) such record date shall be deemed to be the date of the
issuance, sale, distribution or grant in question and (y) if the Company shall legally abandon such
action prior to effecting such action, no adjustment shall be made pursuant to this Section
4 in respect of such action.

          (iv) In computing adjustments under this Section 4, (A) fractional interests in Shares
shall be taken into account to the nearest one-thousandth of a Share, and (B) calculations of the
Exercise Price shall be carried to the nearest one-thousandth of one cent.

     (e) Proceedings Prior to Any Action Requiring Adjustment. As a condition precedent to
the taking of any action which would require an adjustment pursuant to this Section 4, the
Company shall take any action which may be necessary, including obtaining regulatory approvals or
exemptions, in order that the Company may thereafter validly and legally issue as fully paid and
nonassessable all Shares which the Warrant Holder is entitled to receive upon exercise of the
Warrant.

     (f) Notice of Adjustment. Not less than 20 days prior to the record date or effective
date, as the case may be, of any action which requires or might require an adjustment or
readjustment pursuant to this Section 4, the Company shall give notice to the Warrant
Holder of such event, describing such event in reasonable detail and specifying the record date or
effective date, as the case may be, and, if determinable, the required adjustment and computation
thereof. If the required adjustment is not determinable as the time of such notice, the Company
shall give notice to the Warrant Holder of such adjustment and

6

 

computation as soon as reasonably practicable after such adjustment becomes determinable. In
connection with any such adjustment or readjustment, at its sole cost and expense, the Company will
also cause independent certified public accountants of recognized national standing (which may be
the regular auditors of the Company) selected by the Company to verify its computations and confirm
that such computations were made in accordance with this Section 4 and, in connection with
the preparation of the Company’s quarterly financial statements prepare a report setting forth such
adjustment or readjustment and showing in reasonable detail the method of calculation thereof and
the facts upon which such adjustment or readjustment is based, including a statement of (i) the
number of Shares outstanding or deemed to be outstanding, and (ii) the Exercise Price in effect
immediately prior to such issue or sale and as adjusted and readjusted (if required by this
Section 4) on account thereof. The Company will forthwith mail a copy of each such report
to the Warrant Holder and will, upon the written request at any time of the Warrant Holder, furnish
to such holder a like report setting forth the Exercise Price at the time in effect and showing in
reasonable detail how it was calculated. The Company will also keep copies of all such reports at
its office and will cause the same to be available for inspection at such office during normal
business hours by the Warrant Holder or any prospective purchaser of this Warrant designated by the
Warrant Holder.

     (g) Disputes. Any dispute which arises between the Warrant Holder and the Company with
respect to the calculation of the adjusted Exercise Price or Warrant Shares issuable upon exercise
shall be determined by the independent auditors of the Company in accordance with the terms of this
Warrant, and such determination shall be binding upon the Company and the holders of the Warrants
and the Warrant Shares if made in good faith and without manifest error.

     (h) Other Actions Affecting Shares.

          (i) Equitable Equivalent. In case any event shall occur as to which the provisions of
this Section 4 set forth above hereof are not strictly applicable but the failure to make
any adjustment would not, or if the application of the provisions of this Section 4
otherwise would not, in the opinion of the Warrant Holder, fairly protect the purchase rights
represented by this Warrant in accordance with the essential intent and principles of this
Section 4, then, in each such case, at the request of the Requisite Holders, the Company
shall appoint a firm of independent investment bankers of recognized national standing (which shall
be completely independent of the Company and shall be satisfactory to such Warrant Holders), which
shall give their opinion upon the adjustment, if any, on a basis consistent with the essential
intent and principles established in this Section 4, necessary to preserve the purchase
rights of such Warrant Holder represented by this Warrant. Upon receipt of such opinion, the
Company will promptly mail a copy thereof to the holder of this Warrant and shall make the
adjustments described therein. The costs and expenses of such investment bankers shall be borne by
the Company.

          (ii) No Avoidance. The Company shall not, by amendment of its certificate of
incorporation or bylaws or through any consolidation, merger, reorganization, transfer of assets,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of all such action as may be
necessary or appropriate in order to protect the rights of the holder of this Warrant against
dilution or other impairment as if the holder was a stockholder of the Company entitled to the
benefit of fiduciary duties afforded to stockholders under Delaware law.

     (i) Adjustment of Par Value. If for any reason (including the operation of the
adjustment provisions set forth in this Warrant), the Exercise Price on any date of exercise of
this Warrant shall not be lawful and adequate consideration for the issuance of the relevant
Warrant Shares, then the Company shall take such steps as are necessary (including the amendment of
its certificate of incorporation so as to reduce the par value of the Shares) to cause such
Exercise Price to be adequate and lawful consideration on the date the payment thereof is due, but
if the Company shall fail to take such steps, then the Company acknowledges that the Warrant Holder
shall have been damaged by the Company in an amount equal to an amount, that,

7

 

when added to the total Exercise Price for the relevant Warrant Shares, would equal lawful and
adequate consideration for the issuance of such Warrant Shares, and the Company irrevocably agrees
that if the Warrant Holder shall then forgive the right to recover such damages from the Company,
such forgiveness shall constitute, and Company shall accept such forgiveness as, additional lawful
consideration for the issuance of the relevant Warrant Shares.

     (j) Appraisal.

          (i) If the Requisite Holders shall, for any reason whatsoever, disagree with the Company’s
determination of the Appraised Value of a Share, then such holders shall by notice to the Company
(an “Appraisal Notice”) given within sixty (60) days after the Company notifies the holders of such
determination, elect to dispute such determination, and such dispute shall be resolved as set forth
in clause (ii) of this Section.

          (ii) The Company shall within ten (10) days after an Appraisal Notice has been given, engage
an independent investment bank of national repute (the “Appraiser”) selected by the Requisite
Holders and retained pursuant to an engagement letter between the Company and the Appraiser with
respect to such valuation in form and substance reasonably acceptable to Requisite Holders, to make
an independent determination of the Appraised Value of a Share; such value shall be determined
without deduction for (a) liquidity considerations, (b) minority stockholder status, or (c) any
liquidation or other preference or any right of redemption in favor of any other equity securities
of the Company. The costs of engagement of such investment bank for any such determination of
Appraised Value shall be paid by the Company.

     Section 5. Restrictions on Exercise. The Company shall provide to the Warrant Holder
prompt written notice of any time that the Company is unable to issue the Warrant Shares via DTC
transfer (or otherwise without restrictive legend), because (A) the Commission has issued a stop
order with respect to the Registration Statement on Form S-3 (File No. 333-166514) (the
“Registration Statement”), (B) the Commission otherwise has suspended or withdrawn the
effectiveness of the Registration Statement, either temporarily or permanently, or (C) the
Registration Statement is otherwise not then effective (each a “Restrictive Legend Event”);
provided, however, that notwithstanding the foregoing, the Company shall use best efforts to keep a
registration statement covering the issuance or resale of the Warrant Shares effective until the
earliest of (i) the time that this Warrant has expired and (ii) the exercise in full of this
Warrant. To the extent that a Restrictive Legend Event occurs after the Warrant Holder has
exercised this Warrant but prior to the delivery of the Warrant Shares, the Company shall promptly
inform the Warrant Holder thereof and the Warrant Holder may, at its election, (i) if the average
Closing Price of the Shares over the last five consecutive trading days is greater than the
Exercise Price, provide written notice to the Company to, and the Company shall promptly following
the receipt of such notice, deliver that number of Warrant Shares to the Warrant Holder as should
be delivered in a Cashless Exercise in accordance with clause (b) of Section 2(a), and the
Company shall promptly return to the Warrant Holder all consideration paid to the Company in
connection with the Warrant Holder’s attempted exercise of this Warrant (a “Company-Elected
Conversion”), or (ii) rescind the previously submitted Notice of Exercise and the Company shall
return all consideration paid by Warrant Holder for such shares upon such rescission. The Company
shall provide to the Warrant Holder prompt written notice of the termination of the Restrictive
Legend Event. If a Restricted Legend Event is occurring as of the Expiration Date, the term of this
Warrant shall be extended until the fifth (5th) business day after the termination of
such Restricted Legend Event.

     The Warrant Holder understands that if the Company does not file reports pursuant to either
Section 13(a) or Section 15(d) of the Exchange Act, or if a registration statement covering this
Warrant or the Warrant Shares, as applicable, is not in effect when it desires to sell (i) the
rights to purchase Shares pursuant to this Warrant or (ii) the Shares issuable upon exercise of the
right to purchase, the Warrant Holder may be required to hold such securities for an indefinite
period. The Warrant Holder also understands that any sale of (A) its rights hereunder to purchase
Shares or (B) Shares issued or issuable

8

 

hereunder that might be made by it in reliance upon Rule 144 under the Securities Act may be made
only in accordance with the terms and conditions of Rule 144. The Warrant Holder hereby
acknowledges and agrees that if a registration statement under the Securities Act covering the
Warrant Shares is not effective at the time this Warrant is exercised, the Warrant Holder shall
only be permitted to exercise this Warrant by means of a net issuance pursuant to clause (b) of
Section 2(a). For the avoidance of doubt, the Warrant Holder’s understandings and
acknowledgements set forth above shall in no way affect or limit the Company’s covenants and
obligations under the SPA or this Warrant, including, without limitation, its obligations to file
reports under the Exchange Act and maintain the effectiveness of a registration statement covering
the issuance or resale of the Warrant Shares, nor the Warrant Holder’s rights with respect to a
breach of such covenants and obligations.

     Section 6. Transfer of Warrant. The Warrant Holder upon transfer of the Warrant must
deliver to the Company a duly executed Warrant Assignment in the form of Exhibit B and upon
surrender of this Warrant to the Company, the Company shall execute and deliver a new Warrant with
appropriate changes to reflect such Assignment, in the name or names of the assignee or assignees
specified in the Warrant Assignment or other instrument of assignment and, if the Warrant Holder’s
entire interest is not being transferred or assigned, in the name of the Warrant Holder, and upon
the Company’s execution and delivery of such new Warrant, this Warrant shall promptly be cancelled;
and provided that any assignee shall have all of the rights of the Initial Holder hereunder. The
Warrant Holder shall pay any transfer tax imposed in connection with such assignment (if any). Any
transfer or exchange of this Warrant shall be without charge to the Warrant Holder (except as
provided above with respect to transfer taxes, if any) and any new Warrant issued shall be dated
the date hereof.

     Section 7. Assistance in Disposition of Warrant or Warrant Shares. Notwithstanding any
other provision herein, in the event that it becomes unlawful for the Warrant Holder to continue to
hold the Warrant, in whole or in part, or some or all of the Shares held by it, or restrictions are
imposed on the Warrant Holder by any statute, regulation or governmental authority which, in the
judgment of the Warrant Holder, make it unduly burdensome to continue to hold the Warrant or such
Shares, the Warrant Holder may sell or otherwise dispose of the Warrant (subject to the
restrictions on transfer provided in Section 6) or its Shares, and the Company agrees to provide
reasonable assistance to the Warrant Holder in disposing of the Warrant and such Shares in a prompt
and orderly manner and, at the request of the Warrant Holder, to provide (and authorize the Warrant
Holder to provide) financial and other information concerning the Company to any prospective
purchaser of the Warrant or Shares owned by the Warrant Holder.

     Section 8. Identity of Transfer Agent. The Transfer Agent for the Shares is Mellon
Investor Services LLC. Upon the appointment of any subsequent transfer agent for the Shares, the
Company will mail to the Warrant Holder a statement setting forth the name and address of such
transfer agent.

     Section 9. Lost, Mutilated or Missing Warrants. Upon receipt by the Company of notice
of the loss, theft, destruction or mutilation of any Warrant, and, in the case of loss, theft or
destruction, upon receipt of indemnification satisfactory to the Company (in the case of the
Initial Holder its unsecured, unbonded agreement of indemnity or affidavit of loss shall be
sufficient) or, in the case of mutilation, upon surrender and cancellation of the mutilated
Warrant, the Company shall execute and deliver a new Warrant of like tenor and representing the
right to purchase the same aggregate number of Warrant Shares.

     Section 10. Limitation on Exercise. Notwithstanding anything to the contrary contained
herein, the number of Warrant Shares that may be acquired by the Warrant Holder upon any exercise
of this Warrant (or otherwise in respect hereof) shall be limited to the extent necessary to ensure
that, following such exercise (or other issuance), the total number of Shares then beneficially
owned by the Warrant Holder and any other Persons whose beneficial ownership of Shares would be
aggregated with the Warrant Holder’s for purposes of Section 13(d) of the Exchange Act, does not
exceed 4.999% of the total number

9

 

of then issued and outstanding Shares (including for such purpose the Shares issuable upon such
exercise). For such purposes, beneficial ownership shall be determined in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Warrant Holder that the Company is not representing to such Warrant Holder that
such calculation is in compliance with Section 13(d) of the Exchange Act and such Warrant Holder is
solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 10 applies, the determination of whether this
Warrant is exercisable (in relation to other securities owned by such Warrant Holder) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Warrant Holder, and
the submission of a Notice of Exercise shall be deemed to be the Warrant Holder’s determination of
whether this Warrant is exercisable (in relation to other securities owned by such Warrant Holder)
and of which portion of this Warrant is exercisable, in each case subject to such aggregate
percentage limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above
shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder. For purposes of this Section 10, in determining the
number of outstanding Shares, the Warrant Holder may rely on the number of outstanding Shares as
reflected in (x) the Company’s most recent Form 10-Q or Form 10-K, as the case may be, (y) a more
recent public announcement by the Company or (z) any other notice by the Company or the Company’s
transfer agent setting forth the number of Shares outstanding. Upon the written request of the
Warrant Holder, the Company shall within three Business Days confirm orally and in writing to such
Warrant Holder the number of Shares. This provision shall not restrict the number of Shares which a
Warrant Holder may receive or beneficially own in order to determine the amount of securities or
other consideration that such Warrant Holder may receive in the event of a transaction contemplated
in Section 4 of this Warrant. By written notice to the Company, which will not be effective
until the 61st day after such notice is delivered to the Company, the Warrant Holder may
waive the provisions of this Section 10 (but such waiver will not affect any other holder)
to change the beneficial ownership limitation to 9.999% of the number of Shares outstanding
immediately after giving effect to the issuance of Shares upon exercise of this Warrant, and the
provisions of this Section 10 shall continue to apply. Upon such a change by a Warrant
Holder of the beneficial ownership limitation from such 4.999% limitation to such 9.999%
limitation, the 4.999% beneficial ownership limitation may be reinstated by such Warrant Holder
(but such reinstatement will not affect any other holder) by written notice to the Company, which
will not be effective until the 61st day after such notice is delivered to the Company,
whereupon the provisions of this Section 10 shall continue to apply.

     Section 11. Waivers; Amendments. Any provision of this Warrant may be amended or
waived with (but only with) the written consent of the Company and the Warrant Holder. No failure
or delay of the Company or the Warrant Holder in exercising any power or right hereunder shall
operate as a waiver thereof, nor shall any single or partial exercise of any such right or power,
or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other
or further exercise thereon or the exercise of any other right or power. No notice or demand on the
Company in any case shall entitle the Company to any other or future notice or demand in similar or
other circumstances. The rights and remedies of the Company and the Warrant Holder hereunder are
cumulative and not exclusive of any rights or remedies which it would otherwise have.

     Section 12. Miscellaneous.

     (a) Stockholder Rights. The Warrant shall not entitle any Warrant Holder, prior to the
exercise of the Warrant, to any voting rights as a stockholder of the Company.

     (b) Expenses. The Company shall pay all reasonable expenses of the Warrant Holder,
including reasonable fees and disbursements of counsel, in connection with the preparation of the
Warrant, any waiver or consent hereunder or any amendment or modification hereof (regardless of
whether the same becomes effective), or the enforcement of the provisions hereof; provided that the
Company shall not be

10

 

required to pay any expenses of the Warrant Holder arising solely in connection with a transfer of
the Warrant.

     (c) Successors and Assigns. All the provisions of this Warrant by or for the benefit
of the Company or the Warrant Holder shall bind and inure to the benefit of their respective
successors and assigns.

     (d) Severability. In case any one or more of the provisions contained in this Warrant
shall be invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained herein shall not in any way be affected or
impaired thereby. The parties shall endeavor in good faith negotiations to replace the invalid,
illegal or unenforceable provisions with valid provisions the economic effect of which comes as
close as possible to that of the invalid, illegal or unenforceable provisions.

     (e) Notices. Any notice or other communication hereunder shall be in writing and shall
be sufficient if sent by facsimile or first-class mail or courier, postage prepaid, and addressed
as follows: (a) if to the Company, addressed to the Company at its address for notices as set forth
below its signature hereon or any other address as the Company may hereafter notify to the Warrant
Holder and (b) if to the Warrant Holder, addressed to such address as the Warrant Holder may
hereafter from time to time notify to the Company for the purposes of notice hereunder.

     (f) Equitable Remedies. Without limiting the rights of the Company and the Warrant
Holder to pursue all other legal and equitable rights available to such party for the other
parties’ failure to perform its obligations hereunder, the Company and the Warrant Holder each
hereto acknowledge and agree that the remedy at law for any failure to perform any obligations
hereunder would be inadequate and that each shall be entitled to specific performance, injunctive
relief or other equitable remedies in the event of any such failure, without proof of actual
damages and without posting any bond.

     (g) Continued Effect. Rights and benefits conferred on the holders of Warrant Shares
pursuant to the provisions hereof shall continue to inure to the benefit of, and shall be
enforceable by, such holders, notwithstanding the surrender of the Warrant to, and its cancellation
by, the Company upon the full or partial exercise or repurchase hereof.

     (h) Confidentiality. The Company shall not provide material, non-public information to
the Warrant Holder unless prior to providing such information (i) the Warrant Holder gives its
prior written consent to receiving such information and (ii) the Warrant Holder and the Company
enter into a non-disclosure agreement with respect to such information in a form reasonably
acceptable to both the Warrant Holder and the Company.

     (i) Governing Law. THIS WARRANT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE
INTERNAL LAWS OF THE STATE OF NEW YORK, EXCEPT AS OTHERWISE REQUIRED BY MANDATORY PROVISIONS OF
LAW.

     (j) Section Headings. The section headings used herein are for convenience of
reference only and shall not be construed in any way to affect the interpretation of any provisions
of the Warrant.

[Remainder of Page Intentionally Left Blank]

11

 

     
In Witness Whereof, the Company has caused this Warrant to be duly executed by its
authorized signatory as of the day and year first above written.

	 	 	 	 	 
	 	Alexza Pharmaceuticals, Inc., a Delaware

corporation

 	 
	 	By:  	 	 
	 	 	August J. Moretti 	 
	 	 	Senior Vice President, Chief Financial

Officer, General Counsel and Secretary 	 
	 

			
	Address for Notices:

Facsimile:	 	2091 Stierlin Court

Mountain View, CA 94043

 (650) 944-7999

 

 

Exhibit A to Warrant

Form of Notice of Exercise

____________,20____

To: Alexza Pharmaceuticals, Inc.

     Reference is made to the Warrant dated May __, 2011. Terms defined therein are used herein as
therein defined.

     The undersigned, pursuant to the provisions set forth in the Warrant, hereby irrevocably
elects and agrees to purchase                 Shares, and makes payment herewith in
full therefor at the Exercise Price of $                in the following
form:

	 	o	 	Cash Exercise under Section 2(a).
	 
	 	o	 	Cashless Exercise under Section 2(a).
	 
	 	o	 	Combination exercise under Section 2(a). Specify number of Warrant Shares as to
which Cash Exercise and Cashless Exercise are elected:

	 	 	 	Cash Exercise: ______________
	 
	 	 	 	Cashless Exercise: _______________

     [If the number of Shares as to which the Warrant is being exercised is less than all of the
Shares purchasable thereunder, the undersigned hereby requests that a new Warrant representing the
remaining balance of the Shares be registered in the name of      
, whose
address is:

                    .]

	 	 	 	 	 	 	 

	 	 	[NAME OF WARRANT HOLDER]	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 

	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	[ADDRESS OF WARRANT HOLDER]	 	 

 

 

Exhibit B to Warrant

Form of Warrant Assignment

     Reference is made to the Warrant dated May __, 2011, issued by Alexza Pharmaceuticals, Inc.
Terms defined therein are used herein as therein defined.

     FOR VALUE RECEIVED                 (the “Assignor”) hereby sells, assigns and
transfers all of the rights of the Assignor as set forth in such Warrant, with respect to the
number of Warrant Shares covered thereby as set forth below, to the Assignee(s) as set forth below:

     Number of Warrant Shares

	 	 	 	 	 

	Name(s) of Assignee(s)
	 	Address(es)
	 	Number of Warrant

Shares
	 
	 	 
	 	 
	 	 	 	 	 

     All notices to be given by the Company to the Assignor as Warrant Holder shall be sent to the
Assignee(s) at the above listed address(es), and, if the number of Shares being hereby assigned is
less than all of the Shares covered by the Warrant held by the Assignor, then also to the Assignor.

     In accordance with Section 6 of the Warrant, the Assignor requests that the Company execute
and deliver a new Warrant or Warrants in the name or names of the assignee or assignees, as is
appropriate, or, if the number of Shares being hereby assigned is less than all of the Shares
covered by the Warrant held by the Assignor, new Warrants in the name or names of the assignee or
the assignees, as is appropriate, and in the name of the Assignor.

     Dated:                , 20___

	 	 	 	 	 	 	 

	 	 	[NAME OF ASSIGNOR]	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 
	 	 

	 	 
	 
	 

	 	Name:
	 	 

	 	 
	 

	 	 
	 	 

	 	 
	 
	 

	 	Title:
	 	 

	 	 
	 

	 	 
	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	[ADDRESS OF ASSIGNOR]	 	 

 

 

Appendix A

Black Scholes Option Pricing formula to be used when calculating the value of each new warrant to
purchase one share in the Acquirer shall be:

CAcq = value of each warrant to purchase one share in the Acquirer

SAcq = price of Acquirer’s stock as determined by reference to the average of the
closing prices on the securities exchange or Nasdaq Global Market over the 20-day period ending
three trading days prior to the closing of the Corporate Reorganization described in Section
4(c) if the Acquirer’s stock is then traded on such exchange or system, or the average of the
closing bid or sale prices (whichever is applicable) in the over-the-counter market over the 20-day
period ending three trading days prior to the closing of the Corporate Reorganization if the
Acquirer’s stock is then actively traded in the over-the-counter market, or the then most recently
completed financing if the Acquirer’s stock is not then traded on a securities exchange or system
or in the over-the-counter market.

TAcq = expiration date of new warrants to purchase shares in the Acquirer =
TCorp

tAcq = date of issue of new warrants to purchase shares in the Acquirer

TAcq-tAcq = time until warrant expiration, expressed in years

s = volatility = annualized standard deviation of daily log-returns (using a 262-day annualization
factor) of the Acquirer’s stock price on the securities exchange or Nasdaq Global Market over a
20-day trading period, determined by the Warrant Holders, that is within the 100-day trading period
ending on the trading day immediately after the public announcement of the Corporate Reorganization
described in Section 4(c) if the Acquirer’s stock is then traded on such exchange or
system, or the annualized standard deviation of daily-log returns (using a 262-day annualization
factor) of the closing bid or sale prices (whichever is applicable) in the over-the-counter market
over a 20-day trading period, determined by the Warrant Holder, that is within the 100-day trading
period ending on the trading day immediately after the public announcement of the Corporate
Reorganization if the Acquirer’s stock is then actively traded in the over-the-counter market, or
0.6 (or 60%) if the Acquirer’s stock is not then traded on a securities exchange or system or in
the over-the-counter market.

N = cumulative normal distribution function

ln = natural logarithm

λ = dividend rate of the Acquirer for the most recent 12-month period at the time of closing of the
Corporate Reorganization.

KAcq = strike price of new warrants to purchase shares in the Acquirer =
KCorp * (SAcq
 / SCorp)

r = annual yield, as reported by Bloomberg at time tAcq, of the United States Treasury
security measuring the nearest time TAcq

 

 

Appendix B

Black Scholes Option Pricing formula to be used when calculating the value of each Warrant to
purchase one share in the Company shall be:

CCorp = value of each Warrant to purchase one share in the Company

SCorp = price of Company stock as determined by reference to the average of the closing
prices on the securities exchange or Nasdaq Global Market over the 20-day period ending three
trading days prior to the closing of the Corporate Reorganization described in Section 4(c)
if the Company’s stock is then traded on such exchange or system, or the average of the closing bid
or sale prices (whichever is applicable) in the over-the-counter market over the 20-day period
ending three trading days prior to the closing of the Corporate Reorganization if the Company’s
stock is then actively traded in the over-the-counter market, or the then most recently completed
financing if the Company’s stock is not then traded on a securities exchange or system or in the
over-the-counter market.

TCorp = expiration date of Warrants to purchase shares in the Company

tCorp = date of public announcement of transaction

TCorp-tCorp = time until Warrant expiration, expressed in years

s = volatility = the annualized standard deviation of daily log-returns (using a 262-day
annualization factor) of the Company’s stock price on the securities exchange or Nasdaq Global
Market over a 20-day trading period, determined by the Warrant Holders, that is within the 100-day
trading period ending on the trading day immediately after the public announcement of the Corporate
Reorganization described in Section 4(c) if the Company’s stock is then traded on such
exchange or system, or the annualized standard deviation of daily-log returns (using a 262-day
annualization factor) of the closing bid or sale prices (whichever is applicable) in the
over-the-counter market over a 20-day trading period, determined by the Warrant Holder, that is
within the 100-day trading period ending on the trading day immediately after the public
announcement of the Corporate Reorganization if the Company’s stock is then actively traded in the
over-the-counter market, or 0.6 (or 60%) if the Company’s stock is not then traded on a securities
exchange or system or in the over-the-counter market.

N = cumulative normal distribution function

ln = natural logarithm

λ = dividend rate of the Company for the most recent 12-month period at the time of closing of the
Corporate Reorganization.

KCorp = strike price of warrant

r = annual yield, as reported by Bloomberg at time tCorp, of the United States Treasury
security measuring the nearest time T Corpexv10w1

Exhibit 10.1

SECURITIES PURCHASE AGREEMENT

     This Securities Purchase Agreement (this “Agreement”) is dated as of May 3, 2011, between
Alexza Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified
on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and
collectively the “Purchasers”).

     WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an
effective registration statement under the Securities Act of 1933, as amended, the Company desires
to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to
purchase from the Company, securities of the Company as more fully described in this Agreement.

     NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for
other good and valuable consideration the receipt and adequacy of which are hereby acknowledged,
the Company and each Purchaser agree as follows:

ARTICLE I.

DEFINITIONS

     1.01 Definitions. In addition to the terms defined elsewhere in this Agreement, for
all purposes of this Agreement, the following terms have the meanings set forth in this Section
1.01:

          “Action” shall have the meaning ascribed to such term in Section 3.01(o).

          “Affiliate” means any Person that, directly or indirectly through one or more intermediaries,
controls or is controlled by or is under common control with a Person as such terms are used in and
construed under Rule 405 under the Securities Act.

          “Board of Directors” means the board of directors of the Company.

          “Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal
holiday in the United States or any day on which banking institutions in the State of New York are
authorized or required by law or other governmental action to close.

          “Closing” means the closing of the purchase and sale of the Securities pursuant to Section
2.01.

          “Closing Date” means the Trading Day on which all of the Transaction Documents have been
executed and delivered by the applicable parties thereto, and all conditions precedent to (i) each
Purchaser’s obligations to pay the Subscription Amount and (ii) the Company’s obligations to
deliver the
Securities, in each case, have been satisfied or waived, but in no event later than the third
Trading Day following the date hereof.

          “Commission” means the United States Securities and Exchange Commission.

          “Common Stock” means the common stock of the Company, par value $0.0001 per share, and any
other class of securities into which such securities may hereafter be reclassified or changed.

          “Common Stock Equivalents” means any securities of the Company or the Subsidiaries which would
entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any
debt, preferred stock, right, option, warrant or other instrument that is at any time convertible
into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.

 

 

          “Company Counsel” means Cooley
llp, with offices located at 380 Interlocken Crescent,
Suite 900, Broomfield, CO 80021.

          “Disclosure Schedules” means the Disclosure Schedules of the Company delivered concurrently
herewith.

          “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.

          “Exempt Issuance” means the issuance of (a) shares of Common Stock, options or other equity
awards to employees, officers, directors or consultants of the Company pursuant to any equity
incentive plan filed as exhibits to the Company’s SEC Reports, including, but not limited to, the
Company’s 2005 Equity Incentive Plan, 2005 Non-Employee Directors’ Stock Option Plan and 2005
Employee Stock Purchase Plan, (b) securities exercisable or exchangeable for or convertible into
shares of Common Stock issued and outstanding on the date of this Agreement, provided that such
securities have not been amended since the date of this Agreement to increase the number of such
securities or to decrease the exercise price, exchange price or conversion price of such
securities, and (c) securities issued pursuant to acquisitions, licensing or strategic transactions
approved by a majority of the disinterested directors of the Company, provided that any such
issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or
through its subsidiaries, an operating company or an owner of an asset in a business synergistic
with the business of the Company and shall provide to the Company additional benefits in addition
to the investment of funds, but shall not include a transaction in which the Company is issuing
securities primarily for the purpose of raising capital or to an entity whose primary business is
investing in securities. A Variable Rate Transaction shall not be an Exempt Issuance.

          “GAAP” shall have the meaning ascribed to such term in Section 3.01(m).

          “Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in
Rule 433 of the Securities Act relating to the Securities in the form filed or required to be filed
with the Commission or, if not required to be filed, in the form retained in the Company’s records
pursuant to Rule 433(g) of the Securities Act.

          “Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal,
preemptive right or other restriction other than restrictions imposed by securities laws.

          “Material Adverse Effect” means: (a) a material adverse effect on the Company’s ability to
perform in any material respect its obligations under any Transaction Document, or (b) a material
adverse change in the results of operations, assets, business or financial condition of the Company
and its Subsidiaries, taken as a whole, from that set forth or incorporated by reference in the
Prospectus and Prospectus Supplement; provided, however, that none of the
following, in and of itself or themselves, shall constitute a Material Adverse Effect: (i) changes
in the economy or financial markets generally in the United States or changes that are the result
of acts of war or terrorism, in each case that do not have a disproportionate effect on the Company
or its Subsidiaries; (ii) changes that are the result of factors generally affecting the industry
in which the Company and its Subsidiaries operate that do not have a disproportionate effect on the
Company or its Subsidiaries; and (iii) a decline in the price of the Company’s Common Stock on the
Trading Market, provided that the exception in this clause (iii) shall not prevent or otherwise
affect a determination that any change, effect, circumstance or development underlying such decline
has resulted in, or contributed to, a Material Adverse Effect.

          “Material Permits” shall have the meaning ascribed to such term in Section 3.01(q).

 

 

          “Per
Unit Purchase Price” means $1.35, subject to adjustment for reverse and forward stock
splits, stock dividends, stock combinations and other similar transactions of the Common Stock that
occur after the date of this Agreement.

          “Person” means an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint stock company,
government (or an agency or subdivision thereof) or other entity of any kind.

          “Proceeding” means an action, claim, suit, investigation or proceeding (including, without
limitation, an informal investigation or partial proceeding, such as a deposition), whether
commenced or threatened.

          “Prospectus” means the base prospectus filed with the Registration Statement.

          “Prospectus Supplement” means the supplement to the Prospectus complying with Rule 424(b) of
the Securities Act that is filed with the Commission and delivered by the Company to each Purchaser
before or at the Closing.

          “Registration Statement” means the effective registration statement on Form S-3 with the
Commission file No. 333-166514 which registers the sale of the Shares, the Warrants and the Warrant
Shares to the Purchasers.

          “Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as
such Rule may be amended or interpreted from time to time, or any similar rule or regulation
hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

          “Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as
such Rule may be amended or interpreted from time to time, or any similar rule or regulation
hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

          “SEC Reports” shall have the meaning ascribed to such term in Section 3.01(bb).

          “Securities” means the Shares, the Warrant and the Warrant Shares.

          “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder.

          “Shares” means the shares of Common Stock issued or issuable to each Purchaser pursuant to
this Agreement.

          “Subscription Amount” means, as to each Purchaser, the aggregate amount to be paid for Shares
and Warrants purchased hereunder as specified below such Purchaser’s name on the signature page of
this Agreement and next to the heading “Subscription Amount,” in United States dollars and in
immediately available funds.

          “Subsidiary” means any subsidiary of the Company and shall, where applicable, also include any
direct or indirect subsidiary of the Company formed or acquired after the date hereof but before
the Closing Date.

 

 

          “Trading Day” means a day on which the principal Trading Market for the Common Stock is open
for trading.

          “Trading Market” means any of the following markets or exchanges on which the Common Stock is
listed or quoted for trading on the date in question: the Nasdaq Global Market, the Nasdaq Capital
Market, the Nasdaq Global Select Market, the New York Stock Exchange, the NYSE AMEX or the OTC
Bulletin Board (or any successors to any of the foregoing).

          “Transaction Documents” means this Agreement, the Warrants and any other documents or
agreements executed in connection with the transactions contemplated hereunder.

          “Transfer Agent” means Mellon Investor Services, LLC, the current transfer agent of the
Company, with a mailing address of 520 Pike St. Suite 1220, Seattle, WA 98101 and a facsimile
number of (206) 674-3050, and any successor transfer agent of the Company.

          “Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any
debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive additional shares of Common Stock either (A) at a conversion price, exercise
price or exchange rate or other price that is based upon and/or varies with the trading prices of
or quotations for the shares of Common Stock at any time after the initial issuance of such debt or
equity securities, or (B) with a conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such debt or equity security or upon the
occurrence of specified or contingent events directly or indirectly related to the business of the
Company or the market for the Common Stock or (ii) enters into any agreement, including, but not
limited to, an equity line of credit, whereby the Company may sell securities at a future
determined price. Any Purchaser shall be entitled to obtain injunctive relief against the Company
to preclude any such issuance, which remedy shall be in addition to any right to collect damages.

          “Warrants” means, collectively, the warrants to purchase shares of the Company’s Common Stock
delivered to the Purchasers at the Closing in accordance with Section 2.02(a) hereof, in the form
attached hereto as Exhibit A.

          “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Warrants.

ARTICLE II.

PURCHASE AND SALE

     2.01 Closing. Upon the terms and subject to the conditions set forth herein, the
Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an
aggregate of $16,101,495.90 of Shares and Warrants. At the Closing, each Purchaser shall deliver to
the Company, via wire transfer, immediately available funds equal to such Purchaser’s Subscription
Amount as set forth on the signature page hereto executed by such Purchaser and the Company shall
deliver to each Purchaser its respective Shares and Warrants, as determined pursuant to Section
2.02(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.02
deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections
2.02, 5.01 and 5.02, the Closing shall occur at the offices of Company Counsel or such other
location as the parties shall mutually agree.

     2.02 Deliveries.

          (a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:

 

 

               (i) this Agreement duly executed by the Company;

               (ii) a
legal opinion of Company Counsel, in the form previously provided to
the Purchasers;

               (iii) a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer
Agent to deliver via the Depository Trust Company’s Deposit/Withdrawal At Custodian system (“DWAC”)
that number of Shares equal to such Purchaser’s Subscription Amount divided by the Per Unit
Purchase Price;

               (iv) a Warrant registered in the name of such Purchaser to purchase up to a number of shares
of the Company’s Common Stock equal to 35% of such Purchaser’s Shares, with an exercise price of
$1.755, subject to adjustment as provided therein (such Warrant certificate may be delivered
within three Trading Days of the Closing Date); and

               (v) the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule
172 under the Securities Act).

          (b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to
the Company the following:

               (i) this Agreement duly executed by such Purchaser; and

               (ii) such Purchaser’s Subscription Amount by wire transfer to the account specified in writing
by the Company.

ARTICLE III.

REPRESENTATIONS AND WARRANTIES

     3.01 Representations and Warranties of the Company. Except as set forth, or
incorporated by reference, in the Registration Statement, the Prospectus, the Prospectus Supplement
or the Disclosure Schedules, which disclosures in the Registration Statement, the Prospectus, the
Prospectus Supplement and Disclosure Schedules shall be deemed a part hereof and shall qualify any
representation or warranty otherwise made herein, the Company hereby makes the following
representations and warranties to each Purchaser:

          (a) The Registration Statement was declared effective as of 4:00 p.m. Eastern Time on May 20,
2010. The Company satisfies the eligibility requirements for the use of a registration statement
on Form S-3 in connection with the offering contemplated hereby. The Registration Statement is
effective under the Securities Act and no stop order preventing or suspending the effectiveness of
the Registration Statement or suspending or preventing the use of the Prospectus has been issued by
the Commission and no proceedings for that purpose have been instituted or are threatened by the
Commission. Any required filing of the Prospectus Supplement will be made in the manner and within
the time period required by such Rule 424(b). At the time the Registration Statement and any
amendments thereto became effective, at the date of this Agreement and at the Closing Date, the
Registration Statement and any amendments thereto conformed and will conform in all material
respects to the requirements of the Securities Act and did not and will not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein not misleading; and the Prospectus and any amendments or
supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued
and at the Closing Date, conformed and will conform in all material

 

 

respects to the requirements of
the Securities Act and did not and will not contain an untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading.

          (b) Each Issuer Free Writing Prospectus, if any, as of its issue date and at all subsequent
times through the completion of the public offer and sale of the Securities or until any earlier
date that the Company notified or notifies the Purchasers, did not, does not and will not include
any information that conflicted, conflicts or will conflict with the information contained in the
Registration Statement, the Prospectus, or the Prospectus Supplement, including any document
incorporated by reference therein and any prospectus supplement deemed to be a part thereof that
has not been superseded or modified, or
includes an untrue statement of a material fact or omitted or would omit to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading.

          (c) The documents incorporated by reference in the Registration Statement, Prospectus, or
Prospectus Supplement, when they became effective or were filed with the Commission, as the case
may be, conformed in all material respects to the requirements of the Securities Act or the
Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and none of
such documents contained any untrue statement of a material fact or omitted to state any material
fact required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading; and any further documents so filed and
incorporated by reference in the Registration Statement, Prospectus, or Prospectus Supplement, when
such documents become effective or are filed with the Commission, as the case may be, will conform
in all material respects to the requirements of the Securities Act or the Exchange Act, as
applicable, and the rules and regulations of the Commission thereunder and will not contain any
untrue statement of a material fact or omit to state any material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they
were made, not misleading.

          (d) The Company is not an “ineligible issuer” in connection with the offering pursuant to
Rules 164, 405 and 433 under the Securities Act. The Company will file with the Commission all
Issuer Free Writing Prospectuses (other than a “road show,” as defined in Rule 433(h)(4) of the
Securities Act, if any, in the time and manner required under Rules 163(b)(2) and 433(d) of the
Securities Act.

          (e) The Company has been duly organized and is validly existing as a corporation in good
standing (or the foreign equivalent thereof) under the laws of its jurisdiction of organization.
The Company is duly qualified to do business and is in good standing as a foreign corporation in
each jurisdiction in which its ownership or lease of property or the conduct of its business
requires such qualification and has all power and authority (corporate or other) necessary to own
or hold its properties and to conduct the business in which it is engaged, except where the failure
to so qualify or have such power or authority would not have a Material Adverse Effect.

          (f) The Company has the full right, power and authority to enter into this Agreement, and
dated as of the date hereof by and between the Company and the Purchasers, and to perform and to
discharge its obligations hereunder and thereunder; this Agreement has been duly authorized,
executed and delivered by the Company; the Warrants, when executed and delivered pursuant to the
terms of this Agreement, will be duly authorized, executed and delivered by the Company and the
Agreement constitutes, and the Warrant, when executed and delivered, will constitute a valid and
binding obligation of the Company enforceable in accordance with its terms, except (i) as
enforceability may be limited by applicable bankruptcy, insolvency, reorganization, or moratorium
or similar laws affecting creditors’ and contracting parties’ rights generally, and (ii) as
enforceability may be subject to general principles of equity and except as rights to indemnity and
contribution may be limited by state or federal securities laws or
public

 

 

policy underlying such
laws.

          (g) The Common Stock to be issued and sold by the Company to the Purchaser hereunder has been
duly and validly authorized and, when issued and delivered against payment therefor as provided
herein, will be duly and validly issued, fully paid and nonassessable free and clear of all Liens
any preemptive or similar rights and will conform to the description thereof contained in the
Registration Statement, Prospectus and Prospectus Supplement. The Warrants have been duly
authorized, and when executed and delivered by the Company, will constitute valid and binding
obligation of the Company enforceable in accordance with their terms, except (i) as enforceability
may be limited by applicable bankruptcy, insolvency, reorganization, or moratorium or similar laws
affecting creditors’ and contracting
parties’ rights generally, and (ii) as enforceability may be subject to general principles of
equity and except as rights to indemnity and contribution may be limited by state or federal
securities laws or public policy underlying such laws. The Warrant Shares have been duly authorized
and reserved for issuance pursuant to the terms of the Warrants, and when issued by the Company
upon valid exercise of the Warrants and payment of the exercise price, will be duly and validly
issued, fully paid and nonassessable, free and clear of all Liens and free of any preemptive or
similar rights and will conform to the description thereof contained in the Registration Statement,
Prospectus and Prospectus Supplement.

          (h) The Company has an authorized capitalization as set forth in the Company’s Annual Report
on Form 10-K for the year ended December 31, 2010, and all of the issued shares of capital stock of
the Company have been duly and validly authorized and issued, are fully paid and non-assessable,
have been issued in compliance with federal and state securities laws, and conform to the
description thereof contained in the Registration Statement, Prospectus and Prospectus Supplement.
As of May 2, 2011, there were 60,184,774 shares of Common Stock issued and outstanding and no
shares of Preferred Stock, par value $0.0001 per share, of the Company issued and outstanding and
21,019,793 shares of Common Stock were issuable upon the exercise, conversion or settlement of all
options, warrants, convertible securities and restricted stock units outstanding as of such date.
Since such date, the Company has not issued any securities, other than Common Stock issued pursuant
to the exercise of stock options previously outstanding under the Company’s stock option and equity
incentive plans, Common Stock issued pursuant to the exercise of warrants and other rights to
purchase or exchange any securities for shares of Common Stock previously outstanding or the
issuance of Common Stock in accordance with the settlement of previously outstanding restricted
stock units or the issuance of Common Stock pursuant to the Company’s employee stock purchase
program. All of the Company’s options, warrants and other rights to purchase or exchange any
securities for shares of the Company’s capital stock have been duly authorized and validly issued
and were issued in compliance with U.S. federal and state securities laws. None of the outstanding
shares of Common Stock were issued in violation of any preemptive rights, rights of first refusal
or other similar rights to subscribe for or purchase securities of the Company. There are no
authorized or outstanding shares of capital stock, options, warrants, preemptive rights, rights of
first refusal or other rights to purchase, or equity or debt securities convertible into or
exchangeable or exercisable for, any capital stock of the Company or any Subsidiary other than
those described above or accurately described in the Registration Statement, Prospectus and
Prospectus Supplement. The description of the Company’s stock option, stock bonus and other stock
plans or arrangements, and the options or other rights granted thereunder, as described in the
Registration Statement, Prospectus and Prospectus Supplement, accurately and fairly present the
information required to be shown therein with respect to such plans, arrangements, options and
rights. The issue and sale of the Securities will not, immediately or with the passage of time,
obligate the Company to issue shares of Common Stock or other securities to any person (other than
the Purchasers) and will not result in a right of any holder of Company securities to adjust the
exercise, conversion, exchange or reset price under such securities.

          (i) None of the Subsidiaries of the Company has any operations, employees or owns any property
nor do any of the Subsidiaries conduct any business.

 

 

          (j) The execution, delivery and performance of this Agreement and the Warrants by the Company,
the issue and sale of the Securities by the Company and the consummation of the transactions
contemplated hereby, and the issuance of the Warrant Shares upon due exercise of the Warrant in
accordance with their terms, will not (with or without notice or lapse of time or both) conflict
with or result in a breach or violation of any of the terms or provisions of, constitute a default
or Debt Repayment Triggering Event (as defined below) under, give rise to any right of termination
or other right or the cancellation or acceleration of any right or obligation or loss of a benefit
under, or give rise to the creation or imposition of any Lien upon any property or assets of the
Company pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or
instrument to which the Company is a
party or by which the Company is bound or to which any of the property or assets of the
Company is subject, nor will such actions result in any violation of the provisions of the charter
or by-laws (or analogous governing instruments, as applicable) of the Company or any law, statute,
rule, regulation, judgment, order or decree of any court or governmental agency or body, domestic
or foreign, having jurisdiction over the Company or any of their properties or assets. A “Debt
Repayment Triggering Event” means any event or condition that gives, or with the giving of notice
or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness
(or any person acting on such holder’s behalf) the right to require the repurchase, redemption or
repayment of all or a portion of such indebtedness by the Company.

          (k) Except for the registration of the Securities under the Securities Act and such consents,
approvals, authorizations, registrations or qualifications as may be required under the Exchange
Act and applicable state or foreign securities laws and the rules and regulations of The NASDAQ
Stock Market LLC (“Nasdaq”) in connection with the offering and sale of the Securities by the
Company, no consent, approval, authorization or order of, or filing, qualification or registration
with, any court or governmental agency or body, foreign or domestic, which has not been made,
obtained or taken and is not in full force and effect, is required for the execution, delivery and
performance of this Agreement, and the Warrants by the Company, the offer or sale of the Securities
or the consummation by the Company of the transactions contemplated hereby, or in connection with
the issuance of the Warrant Shares upon due exercise of the Warrants in accordance with its terms.

          (l) Ernst & Young LLP, who have audited the Company’s consolidated balance sheets as of
December 31, 2010 and 2009 and the consolidated statements of operations, stockholders’ equity, and
cash flows for each of the three years in the period ended December 31, 2010, and for the period
from December 19, 2000 (inception) to December 31, 2010 and the Company’s internal control over
financial reporting, is an independent registered public accounting firm as required by the
Securities Act and the Public Company Accounting Oversight Board (United States) (the “PCAOB”).
Except as pre-approved in accordance with the requirements set forth in Section 10A of the Exchange
Act, Ernst & Young LLP have not been engaged by the Company to perform any “prohibited activities”
(as defined in Section 10A of the Exchange Act).

          (m) The financial statements, together with the related notes, included or incorporated by
reference in the Registration Statement, Prospectus or the Prospectus Supplement fairly present, in
all material respects, the financial position and the results of operations and changes in
financial position of the Company and its consolidated subsidiaries and other consolidated entities
at the respective dates or for the respective periods therein specified. Such statements and
related notes have been prepared in accordance with the generally accepted accounting principles in
the United States (“GAAP”) applied on a consistent basis throughout the periods. The financial
statements, together with the related notes, included or incorporated by reference in the
Registration Statement, Prospectus or the Prospectus Supplement comply in all material respects
with the Securities Act and the Exchange Act and the rules and regulations under the Exchange Act.
No other financial statements or supporting schedules or exhibits are required by

 

 

the Securities
Act to be described, or included or incorporated by reference in the Registration Statement,
Prospectus or the Prospectus Supplement. There is no pro forma or as adjusted financial information
which is required to be included in the Registration Statement, Prospectus or the Prospectus
Supplement or a document incorporated by reference therein in accordance with the Securities Act
which has not been included or incorporated as so required. The pro forma and pro forma as adjusted
financial information and the related notes included or incorporated by reference in the
Registration Statement, Prospectus and Prospectus Supplement have been properly compiled and
prepared in accordance with the applicable requirements of the Securities Act and present fairly
the information shown therein, and the assumptions used in the preparation thereof are reasonable
and the adjustments used therein are appropriate to give effect to the transactions and
circumstances referred to therein.

          (n) The Company has not sustained, since the date of the latest audited financial statements
included or incorporated by reference in the Registration Statement, Prospectus and Prospectus
Supplement, any material loss or interference with its business from fire, explosion, flood or
other calamity, whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree; and, since such date, with respect to clauses (i), (iii),
(iv) and (v) of this paragraph (q), otherwise than as set forth or contemplated in the Registration
Statement, Prospectus and Prospectus Supplement (i) the Company has not incurred any material
liabilities or obligations, direct or contingent, or entered into any material transactions, other
than in the ordinary course of business and required to be reflected in the Company’s consolidated
financial statements pursuant to GAAP or as required to be disclosed in filings made by the Company
with the Commission, (ii) the Company has not declared or paid any dividends or made any
distribution of any kind with respect to its capital stock; (iii) there has not been any change in
the capital stock of the Company (other than a change in the number of outstanding shares of Common
Stock due to the issuance of shares upon the exercise of options or warrants or in accordance with
the settlement of restricted stock awards or restricted stock units previously outstanding under
the Company’s existing stock awards plans, or any new grants thereof in the ordinary course of
business, or the issuance of shares under the Company’s employee stock purchase plan), (iv) there
has not been any material change in the Company’s long-term or short-term debt required to be
reflected in the Company’s consolidated financial statements pursuant to GAAP or required to be
disclosed in filings made by the Company with the Commission, and (v) there has not been an
occurrence that has had or could reasonably be expected to have, individually or in the aggregate,
a Material Adverse Effect.

          (o) There is no Action (as defined below) to which the Company or any Subsidiary is a party or
of which any property or assets of the Company or any Subsidiary is the subject which is required
to be described in the Registration Statement, Prospectus and Prospectus Supplement or a document
incorporated by reference therein and is not described therein, or which, singularly or in the
aggregate, if determined adversely to the Company or any Subsidiary, could have a Material Adverse
Effect or prevent the consummation of the transactions contemplated hereby. “Action” means any
action, claim, suit, inquiry, notice of violation, proceeding (including any partial proceeding
such as a deposition) or investigation pending or, to the knowledge of the Company, threatened,
against the Company or any Subsidiary of the Company or any of their respective properties before
or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign).

          (p) Neither the Company nor any Subsidiary is in (i) violation of its charter or by-laws (or
analogous governing instrument, as applicable), (ii) default in any respect, and no event has
occurred which, with notice or lapse of time or both, would constitute such a default, in the due
performance or observance of any term, covenant or condition contained in any indenture, mortgage,
deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by
which it is bound or to which any of its property or assets is subject or (iii) violation in any
respect of any law, ordinance, governmental rule, regulation or court order, decree or judgment to
which it or its property or assets may be subject except, in the case of clauses (ii) and (iii) of
this paragraph (p), for any violations or defaults

 

 

that, singularly or in the aggregate, would not
have a Material Adverse Effect.

          (q) The Company has applied for and is pursuing in due course, all licenses, certificates,
authorizations and permits issued by, and have made all declarations and filings with, the
appropriate local, state, federal or foreign regulatory agencies or bodies which are necessary or
desirable for the ownership of its properties or the conduct of its business as described in the
Registration Statement, Prospectus and Prospectus Supplement (collectively, the “Material Permits”)
except where any failures to possess, apply for, pursue or make the same, singularly or in the
aggregate, would not have a Material Adverse Effect. The Company is in compliance with all such
issued Material Permits; all such issued Material Permits are valid and in full force and effect
and, as to pending applications therefor, are not
based on any misrepresentation or omission of any material fact, except where the validity,
misrepresentation, omission, or failure to be in full force and effect would not, singularly or in
the aggregate, have a Material Adverse Effect. All such issued Material Permits are, and if issued
on pending applications are expected to be, free and clear of any restriction or condition that are
in addition to, or materially different from those normally applicable to similar licenses,
certificates, authorizations and permits. The Company has not received notification of any
revocation or modification (or proceedings related thereto) of any such Material Permit and the
Company has no reason to believe that any such issued Material Permit will not be renewed or, as to
any pending application for a Material Permit, that such Permit will not be issued. The Company is
in compliance with any post-issuance requirements of such issued Material Permits and, as to
pending applications thereof, expect to be able to comply (or ensure that third parties acting for
the Company comply) with any such requirements including, without limitation, any such requirements
set forth in applicable sections of 21 C.F.R. Parts 211 and 820 as to quality controls and Good
Manufacturing Practices, or, alternatively, the Company has determined that such compliance is not
required by applicable law.

          (r) Neither the Company nor any of its Subsidiaries is or, after giving effect to the offering
of the Securities and the application of the proceeds thereof as described in the Registration
Statement, Prospectus and Prospectus Supplement, will become an “investment company” within the
meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the
Commission thereunder.

          (s) Neither the Company, its Subsidiaries nor, to the knowledge of the Company, any of the
Company’s or its Subsidiaries’ officers, directors or affiliates has taken or will take, directly
or indirectly, any action designed or intended to stabilize or manipulate the price of any security
of the Company, or which caused or resulted in, or which could in the future reasonably be expected
to cause or result in, stabilization or manipulation of the price of any security of the Company.

          (t) To the knowledge of the Company, the Company owns or possess the right to use all patents,
trademarks, trademark registrations, service marks, service mark registrations, trade names,
copyrights, licenses, inventions, software, databases, know-how, Internet domain names, trade
secrets and other unpatented and/or unpatentable proprietary or confidential information, systems
or procedures, and other intellectual property (collectively, “Intellectual Property”) necessary to
carry on its business as currently conducted and as proposed to be conducted as described in the
Registration Statement, Prospectus and Prospectus Supplement, and the Company is not aware of any
claim to the contrary or any challenge by any other person to the rights of the Company with
respect to the foregoing except for those that could not reasonably be expected to have a Material
Adverse Effect. The Intellectual Property licenses described in the Registration Statement,
Prospectus and Prospectus Supplement are valid, binding upon, and enforceable by or against the
parties thereto in accordance to its terms. The Company has complied in all material respects with,
and is not in breach nor has received any asserted or threatened claim of breach of, any such
Intellectual Property license, and the Company has no knowledge of any breach or anticipated breach
by any other person to any such Intellectual Property license. To the knowledge of the Company,

 

 

the
Company’s business as now conducted and as proposed to be conducted as described in the
Registration Statement, Prospectus and Prospectus Supplement do not infringe or conflict with any
patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses or other
Intellectual Property or franchise right of any person. No claim has been made against the Company
or any of its Subsidiaries alleging the infringement by the Company or any of its Subsidiaries of
any patent, trademark, service mark, trade name, copyright, trade secret, license in or other
intellectual property right or franchise right of any person. The Company has taken all reasonable
steps to protect, maintain and safeguard its rights in all material Intellectual Property,
including the execution of appropriate nondisclosure and confidentiality agreements. The
consummation of the transactions contemplated by this Agreement will not result in the loss or
impairment of or payment of any additional amounts with respect
to, nor require the consent of any other person in respect of, the Company’s right to own,
use, or hold for use any of the Intellectual Property as owned, used or held for use in the conduct
of the business as currently conducted. With respect to the use of the software in the Company’s’
business as it is currently conducted, the Company has not experienced any material defects in such
software including any material error or omission in the processing of any transactions other than
defects which have been corrected, and to the knowledge of the Company, no such software contains
any device or feature designed to disrupt, disable, or otherwise impair the functioning of any
software or, if owned by the Company, is subject to the terms of any “open source” or other similar
license that provides for the source code of the software to be publicly distributed or dedicated
to the public. The Company has at all times complied in all material respects with all applicable
laws relating to privacy, data protection, and the collection and use of personal information
collected, used, or held for use by the Company in the conduct of the Company’s business. No claims
have been asserted or, to the knowledge of the Company, threatened against the Company or any of
its Subsidiaries alleging a violation of any person’s privacy or personal information or data
rights and the consummation of the transactions contemplated hereby will not breach or otherwise
cause any violation of any law related to privacy, data protection, or the collection and use of
personal information collected, used, or held for use by the Company or any of its Subsidiaries in
the conduct of the Company’s their respective businesses. The Company takes reasonable measures to
ensure that such information is protected against unauthorized access, use, modification, or other
misuse.

          (u) The Company has good and marketable title in fee simple to, or have valid rights to lease
or otherwise use, all items of real or personal property which are material to the business of the
Company taken as a whole, in each case free and clear of all Liens that do not, singularly or in
the aggregate, materially affect the value of such property and do not interfere with the use made
and proposed to be made of such property by the Company; and all of the real property leases and
subleases material to the business of the Company, considered as one enterprise, and under which
the Company holds properties described in the Registration Statement, Prospectus and Prospectus
Supplement, are in full force and effect, and the Company has not received any notice of any
material claim of any sort that has been asserted by anyone adverse to the rights of the Company
under any of the real property leases or subleases mentioned above, or affecting or questioning the
rights of the Company to the continued possession of the leased or subleased premises under any
such lease or sublease.

          (v) No labor disturbance by the employees of the Company exists or, to the best of the
Company’s knowledge, is imminent, and the Company is not aware of any existing or imminent labor
disturbance by the employees of any of its principal suppliers, manufacturers, customers or
contractors, that could reasonably be expected, singularly or in the aggregate, to have a Material
Adverse Effect. The Company is not aware that any key employee or significant group of employees of
the Company plans to terminate employment with the Company. No executive officer, to the knowledge
of the Company, is, or is now expected to be, in violation of any material term of any employment
contract, confidentiality, disclosure or proprietary information agreement or non-competition
agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and, to the knowledge of the Company, the continued employment of each such executive
officer does not subject the Company to any liability

 

 

with respect to any of the foregoing matters.
The Company is in compliance with all U.S. federal, state, local and foreign laws and regulations
relating to employment and employment practices, terms and conditions of employment and wages and
hours, except where the failure to be in compliance has not had and could not, individually or in
the aggregate, have or reasonably be expected to have a Material Adverse Effect.

          (w) No “prohibited transaction” (as defined in Section 406 of the Employee Retirement Income
Security Act of 1974, as amended, including the regulations and published interpretations
thereunder (“ERISA”), or Section 4975 of the Internal Revenue Code of 1986, as amended from time to
time (the “Code”)) or “accumulated funding deficiency” (as defined in Section 302 of ERISA) or any
of the events
set forth in Section 4043(b) of ERISA (other than events with respect to which the thirty
(30)-day notice requirement under Section 4043 of ERISA has been waived) has occurred or could
reasonably be expected to occur with respect to any employee benefit plan of the Company which
could reasonably be expected to have, singularly or in the aggregate, a Material Adverse Effect.
Each employee benefit plan of the Company is in compliance in all material respects with applicable
law, including ERISA and the Code. The Company has not incurred and could not reasonably be
expected to incur liability under Title IV of ERISA with respect to the termination of, or
withdrawal from, any pension plan (as defined in ERISA). Each pension plan for which the Company
would have any liability that is intended to be qualified under Section 401(a) of the Code is so
qualified, and nothing has occurred, whether by action or by failure to act, which could reasonably
be expected to cause, singularly or in the aggregate, the loss of such qualification.

          (x) The Company and its Subsidiaries are in compliance with all foreign, federal, state and
local rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous
or toxic substances or waste and protection of health and safety or the environment which are
applicable to their businesses (“Environmental Laws”), except where the failure to comply would
not, singularly or in the aggregate, have a Material Adverse Effect. There has been no storage,
generation, transportation, handling, treatment, disposal, discharge, emission, or other release of
any kind of toxic or other wastes or other hazardous substances by, due to, or caused by the
Company or any of its Subsidiaries (or, to the Company’s knowledge, any other entity for whose acts
or omissions the Company or any of its Subsidiaries is or may otherwise be liable) upon any of the
property now or previously owned or leased by the Company or any of its Subsidiaries, or upon any
other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment,
decree or permit which would, under any law, statute, ordinance, rule (including rule of common
law), regulation, order, judgment, decree or permit, give rise to any liability, except for any
violation or liability which would not have, singularly or in the aggregate with all such
violations and liabilities, a Material Adverse Effect; and there has been no disposal, discharge,
emission or other release of any kind onto such property or into the environment surrounding such
property of any toxic or other wastes or other hazardous substances with respect to which the
Company has knowledge, except for any such disposal, discharge, emission, or other release of any
kind which would not have, singularly or in the aggregate with all such discharges and other
releases, a Material Adverse Effect. In the ordinary course of business, the Company and its
Subsidiaries conduct periodic reviews of the effect of Environmental Laws on their business and
assets, in the course of which they identify and evaluate associated costs and liabilities
(including, without limitation, any capital or operating expenditures required for clean-up,
closure of properties or compliance with Environmental Laws or Material Permits issued thereunder,
any related constraints on operating activities and any potential liabilities to third parties). On
the basis of such reviews, the Company and its Subsidiaries have reasonably concluded that such
associated costs and liabilities would not have, singularly or in the aggregate, a Material Adverse
Effect.

          (y) The Company and each of its Subsidiaries, (i) has timely filed all necessary federal,
state, local and foreign tax returns, and all such returns were true, complete and correct, (ii)
has paid all federal,

 

 

state, local and foreign taxes, assessments, governmental or other charges
due and payable for which it is liable, including, without limitation, all sales and use taxes and
all taxes which the Company or any of its Subsidiaries is obligated to withhold from amounts owing
to employees, creditors and third parties, and (iii) does not have any tax deficiency or claims
outstanding or assessed or, to the best of its knowledge, proposed against any of them, except
those, in each of the cases described in clauses (i), (ii) and (iii) of this paragraph (y), that
would not, singularly or in the aggregate, have a Material Adverse Effect or are in good faith
disputed and for which adequate reserves have been established on the Company’s balance sheet in
accordance with GAAP. The Company and its Subsidiaries, each has not engaged in any transaction
which is a corporate tax shelter or which could reasonably be characterized as such by the Internal
Revenue Service or any other taxing authority. The accruals and reserves on the books and
records of the Company and its Subsidiaries in respect of tax liabilities for any taxable
period not yet finally determined are adequate to meet any assessments and related liabilities for
any such period, and since December 31, 2010, the Company and its Subsidiaries each has not
incurred any liability for taxes other than in the ordinary course. The term “taxes” mean all
federal, state, local, foreign, and other net income, gross income, gross receipts, sales, use, ad
valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll,
employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs,
duties or other taxes, fees, assessments, or charges of any kind whatever, together with any
interest and any penalties, additions to tax, or additional amounts with respect thereto. The term
“returns” means all returns, declarations, reports, statements, and other documents required to be
filed in respect to taxes.

          (z) The Company carries, or is covered by, insurance provided by recognized, financially sound
and reputable institutions with policies in such amounts and covering such risks as is reasonably
believed by the Company to be adequate for the conduct of its business and the value of its
properties and as is customary for companies engaged in similar businesses in similar industries.
The Company has no reason to believe that it will not be able (i) to renew its existing insurance
coverage as and when such policies expire or (ii) to obtain comparable coverage from similar
institutions as may be necessary or appropriate to conduct its business as now conducted and at a
cost that would not result in a Material Adverse Effect. The Company has not been denied any
insurance coverage that they have sought or for which they have applied.

          (aa) The Company maintains a system of internal accounting and other controls sufficient to
provide reasonable assurances that (i) transactions are executed in accordance with management’s
general or specific authorizations; (ii) transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and to maintain accountability for
assets; (iii) access to assets is permitted only in accordance with management’s general or
specific authorization; and (iv) the recorded accountability for assets is compared with existing
assets at reasonable intervals and appropriate action is taken with respect to any differences.
Except as described in the Registration Statement, Prospectus and Prospectus Supplement, since the
end of the Company’s most recent audited fiscal year, there has been (A) no material weakness in
the Company’s internal control over financial reporting (whether or not remediated) and (B) no
change in the Company’s internal control over financial reporting that has materially affected, or
is reasonably likely to materially affect, the Company’s internal control over financial reporting.
The Company has established disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and procedures to
ensure that information required to be disclosed by the Company in the reports it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within the time periods
specified in the Commission’s rules and forms.

          (bb) All agreements and other documents that were required to be filed as exhibits to all
reports required to be filed by the Company under the Securities Act and the Exchange Act,
including pursuant to Section 13(a) or 15(d) thereof, since January 1, 2007 (collectively, the “SEC
Reports”) under Item 601 of

 

 

Regulation S-K to which the Company is a party, have been filed by the
Company as exhibits to the SEC Reports. All agreements referenced in the foregoing sentence
pursuant to which the Company, on the one hand, or any third party, on the other hand, have
continuing rights or obligations as of the date of this Agreement (“Material Agreements”) are valid
and enforceable against the Company, and to the knowledge of the Company, against the other parties
thereto, in accordance with their respective terms, except (i) as enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, or moratorium or similar laws affecting
creditors’ and contracting parties’ rights generally, and (ii) as enforceability may be subject to
general principles of equity and except as rights to indemnity and contribution may be limited by
state or federal securities laws or public policy underlying such laws. The Company is not in
breach of or default under any of the Material Agreements, and to the knowledge of
the Company, no other party to a Material Agreement is in breach of or default under such
Material Agreement. The Company has not received a notice of termination nor is the Company
otherwise aware of any threats to terminate any of the Material Agreements. Neither the Company,
its Subsidiaries nor, to its knowledge, any other party is in violation, breach or default of any
Material Agreement that is reasonably likely to result in a Material Adverse Effect.

          (cc) No relationship, direct or indirect, exists between or among the Company on the one hand,
and the directors, officers, stockholders (or analogous interest holders), customers or suppliers
of the Company or any of their affiliates on the other hand, which is required to be described in
the Registration Statement, Prospectus and Prospectus Supplement or a document incorporated by
reference therein and which is not so described.

          (dd) No person or entity has the right to require registration of shares of Common Stock or
other securities of the Company because of the filing or effectiveness of the Registration
Statement or the issuance and sale of the Securities pursuant hereto, except for persons and
entities who have expressly waived such right in writing or who have been given timely and proper
written notice and have failed to exercise such right within the time or times required under the
terms and conditions of such right. Except as described in the Registration Statement, Prospectus
and Prospectus Supplement, there are no persons with registration rights or similar rights to have
any securities registered by the Company under the Securities Act.

          (ee) The Company does not own any “margin securities” as that term is defined in Regulation U
of the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), and none of
the proceeds of the sale of the Securities will be used, directly or indirectly, for the purpose of
purchasing or carrying any margin security, for the purpose of reducing or retiring any
indebtedness which was originally incurred to purchase or carry any margin security or for any
other purpose which could reasonably be expected to cause any of the Securities to be considered a
“purpose credit” within the meanings of Regulation T, U or X of the Federal Reserve Board.

          (ff) Neither the Company nor any Subsidiary is a party to any contract, agreement or
understanding with any person that would give rise to a valid claim against the Company or the
Purchasers for a brokerage commission, finder’s fee or like payment in connection with the offering
and sale of the Securities or any transaction contemplated by this Agreement, the Registration
Statement, Prospectus and Prospectus Supplement.

          (gg) No forward-looking statement (within the meaning of Section 27A of the Securities Act and
Section 21E of the Exchange Act) contained in the Registration Statement, Prospectus and Prospectus
Supplement has been made or reaffirmed by the Company without a reasonable basis or has been
disclosed by the Company other than in good faith.

          (hh) The Company is subject to and in compliance in all material respects with the reporting

 

 

requirements of Section 13 or Section 15(d) of the Exchange Act. The Common Stock is registered
pursuant to Section 12(b) of the Exchange Act and is listed on The Nasdaq Global Market (the
“NGM”), and the Company has taken no action designed to, or reasonably likely to have the effect
of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common
Stock from the NGM, nor has the Company received any notification that the Commission or Financial
Industry Regulatory Authority (“FINRA”) is contemplating terminating such registration or listing.
No consent, approval, authorization or order of, or filing, notification or registration with, the
NGM is required for the listing and trading of the Common Stock on the NGM that will not have been
obtained or filed as of the Closing.

          (ii) The Company is in compliance with all applicable provisions of the Sarbanes-Oxley Act of
2002 and all rules and regulations promulgated thereunder or implementing the provisions thereof
that are in effect as of the date of this Agreement.

          (jj) The Company is in compliance with all applicable corporate governance requirements set
forth in the Nasdaq Stock Market Rules that are in effect as of the date of this Agreement.

          (kk) Neither the Company nor any Subsidiary nor, to the knowledge of the Company, any employee
or agent of the Company or any Subsidiary, has made any contribution or other payment to any
official of, or candidate for, any federal, state, local or foreign office in violation of any
applicable law (including the Foreign Corrupt Practices Act of 1977, as amended) or of the
character required to be disclosed in the Registration Statement, Prospectus and Prospectus
Supplement or a document incorporated by reference therein.

          (ll) There are no transactions, arrangements or other relationships between and/or among the
Company, any of its affiliates (as such term is defined in Rule 405 of the Securities Act) and any
unconsolidated entity, including, but not limited to, any structured finance, special purpose or
limited purpose entity that could reasonably be expected to materially affect the Company’s
liquidity or the availability of or requirements for their capital resources required to be
described in the Registration Statement, Prospectus and Prospectus Supplement or a document
incorporated by reference therein which have not been described as required.

          (mm) There are no outstanding loans, advances (except normal advances for business expenses in
the ordinary course of business) or guarantees or indebtedness by the Company or any of its
Subsidiaries to or for the benefit of any of the officers or directors of the Company, any of its
Subsidiaries or any of their respective family members, except as disclosed in the Registration
Statement, Prospectus and Prospectus Supplement.

          (nn) The statistical and market related data included in the Registration Statement,
Prospectus and Prospectus Supplement are based on or derived from sources that the Company believes
to be reliable and accurate, and such data agree with the sources from which they are derived.

          (oo) The operations of the Company and its Subsidiaries are and have been conducted at all
times in compliance in all material respects with applicable financial recordkeeping and reporting
requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money
Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any Subsidiaries with respect to the
Money Laundering Laws is pending, or to the knowledge of the Company, threatened.

          (pp) Neither the Company nor any of its Subsidiaries nor, to the knowledge of the Company, any

 

 

director, officer, agent, employee or affiliate of the Company or any of its Subsidiaries is
currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the
U.S. Treasury Department (“OFAC”); and the Company will not directly or indirectly use the proceeds
of the transaction contemplated hereby, or lend, contribute or otherwise make available such
proceeds to any Subsidiary, joint venture partner or other person or entity, for the purpose of
financing the activities of any person currently subject to any U.S. sanctions administered by
OFAC.

          (qq) The clinical trials conducted by or on behalf of the Company that are described in the
SEC Reports or the results of which are referred to in the documents relating to this Agreement and
the purchase of the Securities, are the only clinical trials currently being conducted by or on
behalf of the
Company. Nothing has come to the attention of the Company that has caused the Company to
believe that such studies and tests were and, if still pending, are being, conducted not in
accordance with experimental protocols, procedures and controls pursuant to accepted professional
scientific standards and applicable local, state and federal laws, rules, regulations and
guidances, including, but not limited to, the principles of Good Clinical Practice, the Federal
Food, Drug and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312,
and the Company has made all reports, filings and notifications to authorities (“Governmental
Authorities”) required thereunder, including, but not limited to, adverse events (whether or not
statistically significant) and other reports required by 21 C.F.R. § 312.32. In such reports, the
Company have accurately described in all material respects the experimental protocols, procedures
and controls used in conducting such clinical trials as well as clinical results, adverse events
and data analyses obtained therefrom. The descriptions of the results of such studies, tests and
trials (including adverse events) contained in the SEC Reports, if any, are not inconsistent with
the description made to Governmental Authorities of such results in any material respects. Except
as described in the SEC Reports, no results of any other studies or tests have come to the
attention of the Company that have caused the Company to believe that such results call into
question the results described in the SEC Reports of the clinical trials. The Company has not
received any notices or correspondence from the United States Food and Drug Administration (“FDA”)
or any other governmental agency requiring the termination, suspension or modification of any
clinical trials currently conducted by, or on behalf of, the Company or in which the Company has
participated that are described in the SEC Reports, if any, or the results of which are referred to
in the SEC Reports. Nothing has come to the attention of the Company that has caused the Company to
believe that the clinical trials previously conducted by or on behalf of the Company while
conducted by or on behalf of the Company, were not conducted in accordance with experimental
protocols, procedures and controls pursuant to accepted professional scientific standards; the
descriptions of the results of such studies, tests and trials contained in the SEC Reports, if any,
are consistent with such results.

          (rr) The Company and its Board of Directors have taken all necessary action, if any, to render
inapplicable any control share acquisition, business combination, poison pill (including any
distribution under a rights agreement) or other similar anti-takeover provision under the Company’s
certificate of incorporation or the laws of the State of Delaware that is or could become
applicable to any of the Purchasers as of result of the Purchasers and the Company fulfilling their
obligations or exercising their rights under this Agreement, including without limitation, as a
result of the Company’s issuance of the Securities and the Purchasers’ ownership of the Common
Stock and Warrants; provided, however, that, notwithstanding the foregoing, the
Company and its Board of Directors have not taken any action to preclude any Purchaser from
becoming an “interested stockholder” (as defined in Section 203 of the General Corporation Law of
the State of Delaware) as a result of acquisition of the Securities.

          (ss) Based on the Company’s reasonable expectations as to the financial condition of the
Company as of the Closing Date (and assuming the Closing shall have occurred), as of the date of
this Agreement (i) the Company’s fair saleable value of its assets exceeds the amount that will be
required to be paid or in respect of the Company’s existing debts and other liabilities (including
known contingent

 

 

liabilities) as they mature; (ii) the Company’s assets do not constitute
unreasonably small capital to carry on its business for the current fiscal year as now conducted
and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, and projected capital requirements
and capital availability thereof; and (iii) the current cash flow of the Company, together with the
proceeds the Company would receive at the Closing, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or
in respect of its debt when such amounts are required to be paid. The Company does not intend to
incur debts beyond its ability to pay such debts as they mature (taking into account the timing and
amounts of cash to be payable on or in respect of its debt).

          (tt) No approval of the stockholders of the Company under the rules and regulations of Nasdaq
(including Rule 5635 of the Nasdaq Stock Market Rules) is required for the Company to issue and
deliver to the Purchasers the Securities. Any certificate signed by or on behalf of the Company and
delivered to the Purchasers or to counsel for the Purchasers shall be deemed to be a representation
and warranty by the Company to the Purchasers as to the matters covered thereby.

          (uu) The Company has not sold or issued any securities that would be integrated with the
offering of the Securities contemplated by this Agreement pursuant to the Securities Act. None of
the Company, any of its affiliates, and any Person acting on their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to buy any security,
under circumstances that would cause this offering of the Securities to require approval of
stockholders of the Company for purposes of any applicable stockholder approval provisions,
including, without limitation, under the rules and regulations of any exchange or automated
quotation system on which any of the securities of the Company are listed or designated. None of
the Company, its affiliates and any Person acting on their behalf will take any action or steps
referred to in the preceding sentence that would cause the offering of the Securities to be
integrated with other offerings for purposes of any such applicable stockholder approval
provisions.

          (vv) The Company acknowledges and agrees that each Purchaser is acting solely in the capacity
of an arm’s length purchaser with respect to this Agreement and the transactions contemplated
hereby and thereby and that no Purchaser is (i) an officer or director of the Company, (ii) to the
knowledge of the Company, an Affiliate of the Company or (iii) to the knowledge of the Company, a
“beneficial owner” of more than 10% of the shares of Common Stock. The Company further
acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in
any similar capacity) with respect to this Agreement and the transactions contemplated hereby. The
Company further represents to each Purchaser that the Company’s decision to enter into this
Agreement has been based solely on the independent evaluation by the Company and its
representatives.

          (ww) Anything in this Agreement or elsewhere herein to the contrary notwithstanding, it is
understood and acknowledged by the Company that: (i) except pursuant to a non-disclosure agreement
between the Company and any Purchaser, if applicable, the Purchaser has not been asked by the
Company to agree, nor has the Purchaser agreed, to desist from purchasing or selling, long and/or
short, securities of the Company, or “derivative” securities based on securities issued by the
Company or to hold the Shares for any specified term; (ii) past or future open market or other
transactions by the Purchaser, specifically including, without limitation, short sales or
“derivative” transactions, before or after the Closing, may negatively impact the market price of
the Company’s publicly-traded securities; and (iii) the Purchasers shall not be deemed to have any
affiliation with or control over any arm’s length counter-party in any “derivative” transaction.
The Company further understands and acknowledges that, except pursuant to a non-disclosure
agreement between the Company and any Purchaser, if applicable, (y) the Purchasers may engage in
hedging activities at various times during the period that the Shares are outstanding, and (z) such
hedging activities (if any) could reduce the value of the existing stockholders’ equity interests
in the Company at and after the time that the hedging activities are being conducted. The Company

 

 

acknowledges that such aforementioned hedging activities do not constitute a breach of any of this
Agreement or the Warrants.

     3.02 Representations and Warranties of the Purchasers. Each Purchaser, for itself and
for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing
Date to the Company as follows (unless as of a specific date therein):

          (a) The Purchaser is either an individual or an entity duly organized, validly existing and in
good standing (where such concept is recognized) under the laws of the jurisdiction of its
organization with full right, corporate or partnership power and authority to enter into and to
consummate the transactions contemplated by this Agreement and otherwise to carry out its
obligations hereunder and thereunder. The execution and delivery of this Agreement and performance
by the Purchaser of the transactions contemplated by this Agreement have been duly authorized by
all necessary corporate, partnership, limited liability company or similar action, as applicable,
on the part of the Purchaser. Each Transaction Document to which it is a party has been duly
executed by or on behalf of the Purchaser, and when delivered by the Purchaser in accordance with
the terms hereof, assuming due authorization, execution and delivery by the Company thereof, will
constitute the valid and legally binding obligation of the Purchaser, enforceable against it in
accordance with its terms, except: (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies and (iii) insofar as
indemnification and contribution provisions may be limited by applicable law.

          (b) Other than consummating the transactions contemplated hereunder, the Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with the Purchaser,
directly or indirectly executed any purchases or sales, including short sales, of the securities of
the Company during the period commencing as of the time that the Purchaser first became aware of
the transactions contemplated hereunder and ending immediately following the issuance of the press
release described in Section 4.02 below, unless otherwise set forth in a non-disclosure agreement
between the Company and such Purchaser. Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of the Purchaser’s assets and the portfolio managers have no direct knowledge of the
investment decisions made by the portfolio managers managing other portions of the Purchaser’s
assets, the representation set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase Shares covered by
this Agreement. Other than to other Persons party to this Agreement and to representatives of the
Purchaser, the Purchaser has maintained the confidentiality of all disclosures made to it in
connection with this transaction (including the existence and terms of this transaction).
Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a
representation or warranty, or preclude any actions, with respect to the identification of the
availability of, or securing of, available shares to borrow in order to effect short sales or
similar transactions in the future.

          (c) The Purchaser represents that it has received or can obtain on the Commission’s EDGAR
filing system at www.sec.gov the Prospectus and the Prospectus Supplement, which are parts of the
Registration Statement.

 

 

ARTICLE IV.

OTHER AGREEMENTS OF THE PARTIES

     4.01 Warrant Shares. If all or any portion of a Warrant is exercised at a time when
there is an effective registration statement to cover the issuance or resale of the Warrant Shares
or if the Warrant is exercised via cashless exercise more than six months after the date of
issuance of the Warrant (or one year in the event there is not adequate current public information
available with respect to the Company as required by subsection (c) of Rule 144) and the holder is
not and has not been an Affiliate of the Company within the 90 days prior to the date of exercise
of the Warrant, the Warrant Shares issued pursuant to any such exercise shall be issued free of all
legends. If at any time following the date hereof the Registration Statement (or any subsequent
registration statement registering the sale or resale of the Warrant Shares) is not effective or is
not otherwise available for the sale or resale of the Warrant Shares, the Company shall immediately
notify the holders of the Warrants in writing that such registration statement is not then
effective and thereafter shall promptly notify such holders when the registration statement is
effective again and available for the sale or resale of the Warrant Shares (it being understood and
agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to
sell, any of the Warrant Shares in compliance with applicable federal and state securities laws).
The Company shall use best efforts to keep a registration statement effective until the earliest of
(i) the time that the Warrants have expired and (ii) the exercise in full of all Warrants.

     4.02 Securities Laws Disclosure; Publicity. The Company shall (a) by 9:30 a.m. (New
York City time) on May 3, 2011, issue a press release disclosing the material terms of the
transactions contemplated hereby, and (b) by the end of the first Trading Day immediately following
the date hereof, file a Current Report on Form 8-K, which shall include the Transaction Documents
as exhibits thereto. From and after the issuance of such press release, the Company represents to
the Purchasers that it shall have publicly disclosed all material, non-public information delivered
to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective
officers, directors, employees or agents in connection with the transactions contemplated by the
Transaction Documents, unless such information is covered by a non-disclosure agreement between the
Company and such Purchaser, in which case such information will be disclosed in the Company’s
Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2011. The Company and each
Purchaser shall consult with each other in issuing any press releases with respect to the
transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such
press release nor otherwise make any such public statement without the prior consent of the other
parties to the transactions contemplated hereby except if such disclosure is required by law, in
which case the disclosing party shall promptly provide the other party with prior notice of such
public statement or communication. Notwithstanding the foregoing, the Company shall not publicly
disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the
Commission or any regulatory agency or Trading Market, without the prior written consent of such
Purchaser, except (a) as required by federal securities law in connection with the filing of final
Transaction Documents (including signature pages thereto) with the Commission and (b) to the extent
such disclosure is required by law or Trading Market regulations, in which case the Company shall
provide the Purchasers with prior notice of such disclosure permitted under this clause (b).

     4.03 Furnishing of Information. Until the earliest of the time that (i) no Purchaser
is the holder of Warrants or (ii) expiration of the Warrants or (iii) all Warrant Shares having
been issued, the Company covenants to timely file (or obtain extensions in respect thereof and file
within the applicable grace period) all reports required to be filed by the Company after the date
hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting
requirements of the Exchange Act. As long as any Purchaser owns Securities, if the Company is not
required to file reports pursuant to the Exchange Act, it will prepare and furnish to the
Purchasers and make publicly available in accordance with Rule 144(c) such information as is
required for the Purchasers to sell the Securities, including without limitation, under Rule 144.
The Company further covenants that it will take such further action as any

 

 

holder of Securities may reasonably request, to the extent required from time to time to
enable such Person to sell such Securities without registration under the Securities Act, including
without limitation, within the requirements of the exemption provided by Rule 144.

     4.04 Non-Public Information. Except with respect to the material terms and conditions
of the transactions contemplated by the Transaction Documents, the Company covenants and agrees
that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents
or counsel with any material non-public information without the prior identification thereof and
the express prior written consent of a Purchaser. The Company understands and confirms that each
Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the
Company.

     4.05 Use of Proceeds. The Company shall use the net proceeds from the sale of the
Securities hereunder as set forth in the Prospectus Supplement.

     4.06 Reservation of Common Stock. As of the date hereof, the Company has reserved, and
the Company shall continue to reserve and keep available at all times, free of preemptive rights, a
sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares
pursuant to this Agreement and the Warrant Shares pursuant to the exercise of the Warrants.

     4.07 Listing of Common Stock. The Company hereby agrees to use commercially reasonable
efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it
is currently listed, and the Company shall promptly apply to list or quote all of the Shares and
Warrant Shares on such Trading Market and promptly secure the listing or quotation of all of the
Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company
applies to have the Common Stock traded on any other Trading Market, it will then include in such
application all of the Shares and Warrant Shares, and will take such other action as is reasonably
necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other
Trading Market as promptly as possible. The Company will then take all action reasonably necessary
to continue the listing of its Common Stock on a Trading Market and will comply in all respects
with the Company’s reporting, filing and other obligations under the bylaws or rules of such
Trading Market.

     4.08 Subsequent Equity Sales and Current Financing Agreements. From the date hereof
until 90 days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter
into any agreement to issue or announce the issuance or proposed issuance of any shares of Common
Stock or Common Stock Equivalents; provided, however, the immediately preceding
clause in this Section 4.08 shall not apply in respect of an Exempt Issuance. Until the earlier of
(i) 30 days following the date on which the Company receives from the FDA written approval of the
new drug application to market AZ-004 (Staccato loxapine) or (ii) June 30, 2012, neither the
Company nor any Subsidiary shall enter into any Variable Rate Transactions, issue any Common Stock
or Common Stock Equivalents pursuant to the Azimuth equity line of credit entered into on May 26,
2010 by and between the Company and Azimuth
Opportunity Ltd or any other facilities or
agreements currently in place that permit the Company to issue Common Stock or Common Stock
Equivalents or enter into, participate in, utilize, draw-down on any other similar agreements or
facilities that permit the Company to issue equity or debt securities from time to time, or enter
into, utilize or draw-down on any mortgages, indentures, borrowings, financings or credit
facilities, other than Exempt Issuances or offerings subject to the rights contained in Section
4.09 hereof, for consideration.

     4.09 Participation Right in Subsequent Issuances.

          (a) Subject to the terms and conditions of this Section 4.09, until the earlier of (i) the
date on which the Company receives from the FDA written approval of the new drug application to
market AZ-004 (Staccato loxapine) or (ii) June 30, 2012, the Company shall not issue (an
“Issuance”) any securities,

 

 

including additional shares of Company Common Stock, Common Stock
Equivalents or other equity or debt securities, or any other mortgages, indentures, borrowings,
financings or credit facilities (the “Offered Securities”) to any Person (other than an Exempt
Issuance or any Issuance in the form of a distribution, pro rata, to all holders of Company Common
Stock for no consideration), unless, prior to such Issuance, the Company notifies each Purchaser in
writing of the proposed Issuance and grants to each Purchaser or, at such Purchaser’s election, one
of its Affiliates (x) the right to subscribe for and purchase or lend funds, as the case may be, at
the same price and upon the same terms and conditions (including, in the event such securities are
issued as a unit together with other securities, the purchase of such other securities) as the
proposed Issuance (such right, an “Election Right”), up to an amount of Offered Securities
calculated by multiplying the aggregate amount of Offered Securities by a fraction, the numerator
of which equals the Subscription Amount paid by such Purchaser hereunder and the denominator of
which equals the aggregate Subscription Amount paid by all Purchasers hereunder and (y) if all the
Purchasers do not exercise their Election Rights in full, the right of each Purchaser that
exercised its Election Right in full (each, a “Fully Exercising Purchaser”) to elect to purchase,
at the price and on the terms specified in the Issuance Notice and subject to proration as provided
below, up to a portion of such Offered Securities that are not sold pursuant to clause (x) (such
number of Offered Securities being the “Remaining Offered Securities”) (such right, an
“Over-Election Right”) determined as provided in Section 4.09(b), in each case, as long as the
Company’s giving the Purchasers such opportunity to participate in such Issuance does not result in
the violation of any applicable law or regulation or rule of any applicable Trading Market,
provided, however, such exception shall not be construed to exclude the Purchasers from any such
proposed Issuance based upon the fact the transactions contemplated hereby are conducted pursuant
to the Registration Statement.

          (b) The Company shall give notice of any proposed Issuance (the “Issuance Notice”) to each
Purchaser at least fourteen (14) calendar days in advance of such issuance, stating the Company’s
bona fide intention to make such Issuance and the details thereof, including a good faith summary
of the proposed details thereof, including the expected price and terms, if any, upon which it is
offering such Offered Securities and the estimated number of Offered Securities that each Purchaser
may elect to purchase under its Election Right. Within seven calendar (7) days after the receipt
of the Issuance Notice, each Purchaser shall notify the Company in writing of the number of Offered
Securities it will be willing to purchase under its Election Right (an “Election Right Notice”)
and, if it is a Fully Exercising Purchaser, the maximum number of Remaining Offered Securities, if
any, it will be willing to purchase under its Over-Election Right. If each Fully Exercising
Purchaser elects to purchase a number of Remaining Offered Securities that equals or exceeds the
aggregate number of Remaining Offered Securities multiplied by a fraction, the numerator of which
equals the Subscription Amount paid by each Fully Exercising Purchaser hereunder and the
denominator of which equals the aggregate Subscription Amount paid by all Fully Exercising
Purchasers hereunder (for each such Fully Exercising Purchaser, its
“Allocable Portion”), each Fully
Exercising Purchasers shall purchase their Allocable Portion of the Remaining Offered Securities.
Any Fully Exercising Purchaser that elects to purchase a number of Remaining Offered Securities
that is less than its Allocable Portion shall purchase the number of Remaining Offered Securities
set forth in its Election Right Notice and any Remaining Offered Securities shall be allocated on a
pro rata basis among those Fully Exercising Purchasers, if any, who have elected to purchase a
number of Remaining Offered Securities in excess of their Allocable Portion, up to the maximum
number of Remaining Offered Securities set forth in their respective Election Right Notices.
The Company shall give the Purchasers written notice within three (3) days following the
Company’s receipt of the Election Right Notices regarding the number of Offered Securities that
each Purchaser is permitted to Purchase pursuant to this Section 4.09.

          (c) Any Offered Securities that are offered for purchase to, but not purchased by, Purchasers
pursuant to the preceding clauses (a) and (b) of this Section may be issued and sold by the Company in
accordance with its original Issuance Notice.

 

 

     4.10 Equal Treatment of Purchasers. No consideration (including any modification of
any Transaction Document) shall be offered or paid to any Person to amend or consent to a waiver or
modification of any provision of any of the Transaction Documents unless the same consideration is
also offered to all of the parties to the Transaction Documents. For clarification purposes, this
provision constitutes a separate right granted to each Purchaser by the Company and negotiated
separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class
and shall not in any way be construed as the Purchasers acting in concert or as a group with
respect to the purchase, disposition or voting of Securities or otherwise.

     4.11 Shareholder Rights Plan. No claim will be made or enforced by the Company or,
with the consent of the Company, any other Person, that any Purchaser is an “Acquiring Person”
under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter
adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such
plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any
other agreement between the Company and the Purchasers.

     4.12 Indemnification of Purchasers. Subject to the provisions of this
Section 4.12, the Company will indemnify, defend and hold harmless each Purchaser and its
directors, officers, shareholders, members, partners, employees and agents (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such
title or any other title), each Person who controls such Purchaser (within the meaning of Section
15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers,
shareholders, agents, members, partners or employees (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other
title) of such controlling persons (each, a “Purchaser Party”) from any and all losses,
liabilities, obligations, claims, contingencies, damages, costs and expenses, including all
judgments, amounts paid in settlements (except as otherwise provided in this Section 4.12), court
costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may
suffer or incur as a result of or relating to (a) any material breach of any of the
representations, warranties, covenants or agreements made by the Company in this Agreement or in
the other Transaction Documents or (b) any action instituted against a Purchaser in any capacity,
or any of them or their respective Affiliates, by any Person with respect to any of the
transactions contemplated by the Transaction Documents (unless in the case of this clause (b) such
action is based upon a breach of such Purchaser Party’s representations, warranties or covenants
under the Transaction Documents or any violations by such Purchaser Party of state or federal securities
laws or any conduct by such Purchaser Party which constitutes fraud,
gross negligence or willful
misconduct (collectively, the “Carve-Outs”)). If any action shall be brought against
any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such
Purchaser Party shall, to the extent legally permissible, promptly notify the Company in writing,
and
the Company shall have the right to assume the defense thereof with counsel of its own
choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to
employ separate counsel in any such action and participate in the defense thereof, but the fees and
expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that
(i) the employment thereof has been specifically authorized by the Company in writing, (ii) the
Company has failed after a reasonable period of time to assume such defense and to employ counsel
or (iii) in such action there is, in the reasonable written opinion of counsel to the Purchaser
which is furnished to the Company, a material conflict on any material issue between the position
of the Company and the position of such Purchaser Party, in which case the Company shall be
responsible for the reasonable fees and expenses of no more than one such separate counsel. The
Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a
Purchaser Party effected without the Company’s prior written

 

 

consent, which shall not be
unreasonably withheld, conditioned or delayed; or (z) to the extent, but only to the extent that a
loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the
representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement
or in the other Transaction Documents. The Company will have the exclusive right to settle any
claim or proceeding provided that the Company will not settle any such claim, action or proceeding
without the prior written consent of the Purchaser Party, which shall not be unreasonably withheld
or delayed; provided that such consent shall not be required if the settlement includes a full and
unconditional release of the Purchase Party from all liability arising or that may arise out of
such claim or proceeding and does not include a statement as to or an admission or fault,
culpability or a failure to act by or on behalf of any Purchaser Party. To the extent that any
payment made to a Purchaser Party is determined in a final,
non-appealable judgment to have been improper by reason of the underlying
action being based on conduct or circumstances set forth in the definition of the Carve-Outs, such
Purchaser Party will promptly pay the Company such amount.

ARTICLE V.

CLOSING CONDITIONS

     5.01 Conditions to Purchasers’ Obligations. The respective obligations of the
Purchasers hereunder are subject to the accuracy, when made and on the Closing Date, of the
representations and warranties on the part of the Company contained herein, to the accuracy of the
statements of the Company made in any certificates pursuant to the provisions hereof, to the
performance by the Company of its obligations hereunder, the delivery by the Company of the items
set forth in Section 2.02(a) of this Agreement and to each of the following additional terms and
conditions:

          (a) No stop order suspending the effectiveness of the Registration Statement shall have been
issued and no proceedings for that purpose shall have been initiated or threatened by the
Commission, and any request for additional information on the part of the Commission (to be
included in the Registration Statement, the Prospectus or the Prospectus Supplement or otherwise)
shall have been complied with to the reasonable satisfaction of the counsel to the Purchasers.

          (b) The Purchasers shall not have discovered and disclosed to the Company on or prior to the
Closing Date that the Registration Statement, the Prospectus or the Prospectus Supplement or any
amendment or supplement thereto contains an untrue statement of a fact which, in the opinion of
counsel for the Purchasers, is material or omits to state any fact which, in the opinion of such
counsel, is material and is required to be stated therein or is necessary to make the statements
therein not misleading.

          (c) All corporate proceedings and other legal matters incident to the authorization, form,
execution, delivery and validity of each of this Agreement, the Shares, the Warrants, the
Registration Statement, the Prospectus and the Prospectus Supplement and all other legal matters
relating to this Agreement and the transactions contemplated thereby shall be reasonably
satisfactory in all material respects to counsel for the Purchasers, and the Company shall have
furnished to such counsel all documents and information that they may reasonably request to enable
them to pass upon such matters.

          (d) Neither the Company nor any of its Subsidiaries shall have sustained since the date of the
latest audited financial statements included or incorporated by reference in the Prospectus, or as
described in any document incorporated by reference to the Prospectus or the Registration
Statement, any loss or interference with its business from fire, explosion, flood, terrorist act or
other calamity, whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree, otherwise than as set forth in or contemplated by the
Prospectus.

          (e) The Common Stock is registered under the Exchange Act and, as of the Closing Date, the
Shares and Warrant Shares shall be listed and admitted and authorized for trading on The Nasdaq
Global

 

 

Market, and, upon request, satisfactory evidence of such actions shall have been provided to
counsel to the Purchasers. The Company shall have taken no action designed to, or likely to have
the effect of terminating the registration of the Common Stock under the Exchange Act or delisting
or suspending from trading the Common Stock from The Nasdaq Global Market, nor has the Company
received any information suggesting that the Commission or The Nasdaq Global Market is
contemplating terminating such registration or listing.

          (f) No action shall have been taken and no statute, rule, regulation or order shall have been
enacted, adopted or issued by any governmental agency or body which would, as of the Closing Date,
prevent the issuance or sale of the Securities or materially and adversely affect or potentially
and adversely affect the business or operations of the Company; and no injunction, restraining
order or order of any other nature by any federal or state court of competent jurisdiction shall
have been issued as of the Closing Date which would prevent the issuance or sale of the Securities
or materially and adversely affect or potentially and adversely affect the business or operations
of the Company.

          (g) The Company shall have prepared and filed with the Commission a Current Report on Form 8-K
with respect to the issuance of the Securities, including the press release contemplated by Section
4.02 hereof.

          (h) Prior to the Closing Date, the Company shall have furnished to the counsel to the
Purchasers such further information, certificates and documents as such counsel may reasonably
request.

          (i) There shall have been no Material Adverse Effect with respect to the Company since the
date of the latest audited financial statements included or incorporated by reference in the
Prospectus, Prospectus Supplement or Registration Statement.

     5.02 Conditions to Company’s Obligations. The obligations of the Company hereunder are
subject to the accuracy, when made and on the Closing Date, of the representations and warranties
on the part of each Purchaser contained herein, to the accuracy of the statements of each Purchaser
made in any certificates pursuant to the provisions hereof, to the performance by each Purchaser of
its obligations hereunder, the delivery by each Purchaser of the items set forth in Section 2.02(b)
of this Agreement.

ARTICLE VI.

MISCELLANEOUS

     6.01 Termination. This Agreement may be terminated by any Purchaser, as to such
Purchaser’s obligations hereunder only and without any effect whatsoever on the obligations between
the Company and the other Purchasers, by written notice to the other parties, if the Closing has
not been consummated on or before May 11, 2011; provided, however, that such
termination will not affect the right of any party to sue for any breach by any other party (or
parties).

     6.02 Fees and Expenses. Except as expressly set forth in the Transaction Documents to
the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and
other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all
Transfer Agent fees, stamp taxes and other taxes and duties levied in connection with the delivery
of any Securities to the Purchasers.

     6.03 Entire Agreement. The Transaction Documents, together with the exhibits and
schedules thereto, the Prospectus and the Prospectus Supplement, contain the entire understanding
of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and

 

 

understandings, oral or written, with respect to such matters, which the parties
acknowledge have been merged into such documents, exhibits and schedules.

     6.04 Notices. Any and all notices or other communications or deliveries required or
permitted to be provided hereunder shall be in writing and shall be deemed given and effective on
the earliest of: (a) the date of transmission, if such notice or communication is delivered via
facsimile at the facsimile number set forth on the signature pages attached hereto at or prior to
5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of
transmission, if such notice or communication is delivered via facsimile at the facsimile number
set forth on the signature pages attached hereto on a day that is not a Trading Day or later than
5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day
following the date of mailing, if sent by U.S. nationally recognized overnight courier service or
(d) upon actual receipt by the party to whom such notice is required to be given. The address for
such notices and communications shall be as set forth on the signature pages attached hereto.

     6.05 Amendments; Waivers. No provision of this Agreement may be waived, modified,
supplemented or amended except in a written instrument signed, in the case of an amendment, by the
Company and the each of the Purchasers or, in the case of a waiver, by the party against whom
enforcement of any such waived provision is sought. No waiver of any default with respect to any
provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in
the
future or a waiver of any subsequent default or a waiver of any other provision, condition or
requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in
any manner impair the exercise of any such right. If an amendment to this Agreement would have a
disproportionately material adverse effect on the rights or obligations of one or more Purchasers
under this Agreement as compared to the rights and obligations of other Purchasers hereunder, then
such amendment will not be effective as to the Purchasers who are subject to such disproportionate
material adverse effect without the written consent of the holders of a majority of the interest of
the Shares held by such Purchasers based on the initial Subscription Amounts hereunder.

     6.06 Headings. The headings herein are for convenience only, do not constitute a part
of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

     6.07 Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of the parties and their successors and permitted assigns. The Company may not assign this
Agreement or any rights or obligations hereunder without the prior written consent of each
Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this
Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that
such transferee agrees in writing to be bound, with respect to the transferred Securities, by the
provisions of the Transaction Documents that apply to the Purchasers.

     6.08 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns and is not for the benefit of,
nor may any provision hereof be enforced by, any other Person.

     6.09 Governing Law. All questions concerning the construction, validity, enforcement
and interpretation of the Transaction Documents shall be governed by and construed and enforced in
accordance with the internal laws of the State of New York, without regard to the principles of
conflicts of law thereof. Each party agrees that all legal proceedings concerning the
interpretations, enforcement and defense of the transactions contemplated by this Agreement and any
other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby
irrevocably submits to the exclusive jurisdiction of the

 

 

state and federal courts sitting in the
City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in
connection herewith or with any transaction contemplated hereby or discussed herein (including with
respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an
inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of
process and consents to process being served in any such suit, action or proceeding by mailing a
copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to
such party at the address in effect for notices to it under this Agreement and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner
permitted by law. If either party shall commence an action, suit or proceeding to enforce any
provisions of the Transaction Documents, then the prevailing party in such action, suit or
proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other
costs and expenses incurred with the investigation, preparation and prosecution of such action or
proceeding.

     6.10 Survival. The representations, warranties, covenants and agreements contained
herein shall survive the Closing and the delivery of the Securities.

     6.11 Execution. This Agreement may be executed in two or more counterparts, all of
which when taken together shall be considered one and the same agreement and, with respect to the
Company and a Purchaser, shall become effective when counterparts have been signed by the Company
and such Purchaser and delivered to each other, it being understood that the parties need not sign
the same counterpart. In the event that any signature is delivered by facsimile transmission or by
e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding
obligation of the party executing (or on whose behalf such signature is executed) with the same
force and effect as if such facsimile or “.pdf” signature page were an original thereof.

     6.12 Severability. If any term, provision, covenant or restriction of this Agreement
is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in
full force and effect and shall in no way be affected, impaired or invalidated, and the parties
hereto shall use their commercially reasonable efforts to find and employ an alternative means to
achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties
that they would have executed the remaining terms, provisions, covenants and restrictions without
including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

     6.13 Rescission and Withdrawal Right. Notwithstanding anything to the contrary
contained in (and without limiting any similar provisions of) any of the other Transaction
Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein
provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time
upon written notice to the Company, any relevant notice, demand or election in whole or in part
without prejudice to its future actions and rights; provided, however, that in the
case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to
return any shares of Common Stock subject to any such rescinded exercise notice concurrently with
the return to such Purchaser of the aggregate exercise price paid to the Company for such shares
and the restoration of such Purchaser’s right to acquire such shares pursuant to such Purchaser’s
Warrant (including issuance of a replacement warrant certificate evidencing such restored right).

 

 

     6.14 Replacement of Securities. If any certificate or instrument evidencing any
Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued
in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in
lieu of and substitution therefor, a new certificate or instrument, upon receipt by the Company of
notice of such loss, theft or destruction. The applicant for a new certificate or instrument under
such circumstances shall also pay any reasonable third-party costs (including customary indemnity)
associated with the issuance of such replacement Securities.

     6.15 Remedies. In addition to being entitled to exercise all rights provided herein or
granted by law, including recovery of damages, each of the Purchasers and the Company will be
entitled to specific performance under the Transaction Documents, without posting any bond. The
parties agree that monetary damages may not be adequate compensation for any loss incurred by
reason of any breach of obligations contained in the Transaction Documents and hereby agree to
waive and not to assert in any action for specific performance of any such obligation the defense
that a remedy at law would be adequate.

     6.16 Independent Nature of Purchasers’ Obligations and Rights. The obligations of each
Purchaser under any Transaction Document are several and not joint with the obligations of any
other Purchaser, and no Purchaser shall be responsible in any way for the performance or
non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing
contained herein or in any other Transaction Document, and no action taken by any Purchaser
pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an
association, a joint venture or any other kind of entity, or create a presumption that the
Purchasers are in any way acting in concert or as a group with respect to such obligations or the
transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to
independently protect and enforce its rights including, without limitation, the rights arising out
of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any
other Purchaser to be joined as an additional party in any proceeding for such purpose. Each
Purchaser has been represented by its own separate legal counsel in its review and negotiation of
the Transaction Documents. For reasons of administrative convenience only, certain Purchasers and
their respective counsel have chosen to communicate with the Company through Alston & Bird, LLP.
The Company has elected to provide all Purchasers with the same terms and Transaction Documents for
the convenience of the Company and not because it was required or requested to do so by any of the
Purchasers. It is expressly understood and agreed that each provision contained in this Agreement
and in each other Transaction Document is between the Company and a Purchaser, solely, and not
between the Company and the Purchasers collectively and not between and among the Purchasers.

     6.17 Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of
any action or the expiration of any right required or granted herein shall not be a Business Day,
then such action may be taken or such right may be exercised on the next succeeding Business Day.

     6.18 Construction. The parties agree that each of them and/or their respective counsel
have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal
rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments
thereto. In addition, each and every reference to share prices and shares of Common Stock in any
Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock
dividends, stock combinations and other similar transactions of the Common Stock that occur after
the date of this Agreement.

     
6.19 WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION
BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE
GREATEST EXTENT PERMITTED

 

 

BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND
EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

(Signature Pages Follow)

 

 

     IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be
duly executed by their respective authorized signatories as of the date first indicated above.

ALEXZA PHARMACEUTICALS, INC.

	 	 	 	 	 

	By:
	 	/s/ Thomas B. King	 	 
	 

	 	 

	 	 
	Name:
	 	Thomas B. King	 	 
	 

	 	 

	 	 
	Title:
	 	President and Chief Executive Officer	 	 

Address for Notice:

2091 Stierlin Court

Mountain View, CA 94043

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR PURCHASER FOLLOWS]

 

 

[PURCHASER SIGNATURE PAGES TO ALEXZA SECURITIES PURCHASE AGREEMENT]

     IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above.

	 	 	 	 	 

	Name of Purchaser:

	 	RA Capital Healthcare Fund, L.P.	 	 
	 
	 	 	 	 
	Signature of Authorized Signatory of Purchaser:
Name of Authorized Signatory:

	 	/s/ Peter Kolchinsky
 

Peter Kolchinsky
	 	 
	Title of Authorized Signatory:

	 	Manager	 	 

[SIGNATURE PAGES CONTINUE]

 

 

[PURCHASER SIGNATURE PAGES TO ALEXZA SECURITIES PURCHASE AGREEMENT]

     IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above.

	 	 	 	 	 

	Name of Purchaser:

	 	Blackwell Partners, LLC	 	 
	 
	 	 	 	 
	Signature of Authorized Signatory of Purchaser:
Name of Authorized Signatory:

	 	/s/ Geoffrey D. Keegan
 

Geoffrey D. Keegan
	 	 
	Title of Authorized Signatory:

	 	Investment Manager, DUMAC, LLC, Authorized Agent	 	 
	 
	 	 	 	 
	Signature of Authorized Signatory of Purchaser:
Name of Authorized Signatory:

	 	/s/ Bart J. Brunk
 

Bart J. Brunk
	 	 
	Title of Authorized Signatory:

	 	Controller, DUMAC, LLC, Authorized Agent	 	 

[SIGNATURE PAGES CONTINUE]

 

 

[PURCHASER SIGNATURE PAGES TO ALEXZA SECURITIES PURCHASE AGREEMENT]

     IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above.

	 	 	 	 	 

	Name of Purchaser:

	 	Boxer Capital, LLC	 	 
	 
	 	 	 	 
	Signature of Authorized Signatory of Purchaser:
Name of Authorized Signatory:

	 	/s/ Chris Fuglesang
 

Chris Fuglesang
	 	 
	Title of Authorized Signatory:

	 	Member, Counsel	 	 

[SIGNATURE PAGES CONTINUE]

 

 

[PURCHASER SIGNATURE PAGES TO ALEXZA SECURITIES PURCHASE AGREEMENT]

     IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above.

	 	 	 	 	 

	Name of Purchaser:

	 	MVA Investors, LLC	 	 
	 
	 	 	 	 
	Signature of Authorized Signatory of Purchaser:
Name of Authorized Signatory:

	 	/s/ Chris Fuglesang
 

Chris Fuglesang
	 	 
	Title of Authorized Signatory:

	 	President, Member	 	 

[SIGNATURE PAGES CONTINUE]

 

 

[PURCHASER SIGNATURE PAGES TO ALEXZA SECURITIES PURCHASE AGREEMENT]

     IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above.

	 	 	 	 	 

	Name of Purchaser:

	 	Funds and Accounts under Management by BlackRock	 	 
	 

	 	Advisors, LLC and its advisor Affiliates	 	 
	 
	 	 	 	 
	By:

	 	BlackRock Advisors, LLC as investment advisor	 	 
	 
	 	 	 	 
	Signature of Authorized Signatory of Purchaser:
Name of Authorized Signatory:

	 	/s/ Andrew F. Thut
 

Andrew F. Thut
	 	 
	Title of Authorized Signatory:

	 	Managing Director, Portfolio Manager	 	 

 

 

EXHIBIT A

FORM OF WARRANT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}]]